

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number  
**WO 02/38171 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 38/47**,  
A61P 43/00 // C12N 9/24, 15/56

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number: PCT/US01/47835

(22) International Filing Date:  
9 November 2001 (09.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/711,205 9 November 2000 (09.11.2000) US

(71) Applicant (for all designated States except US):  
**BIOMARIN PHARMACEUTICAL, INC.** [US/US];  
371 Bel Marin Keys Boulevard, Suite 210, Novato, CA  
94949 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KAKKIS, Emil, D.**  
[US/US]; 2512 Laguna Vista Drive, Novato, CA 94949  
(US).

(74) Agent: **HALLUIN, Albert, P.**; Howrey Simon Arnold &  
White, LLP, 301 Ravenswood Avenue, Menlo Park, CA  
94025 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Published:**

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF RECOMBINANT  $\alpha$ -L-IDURONIDASE

(57) Abstract: The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant  $\alpha$ -L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including  $\alpha$ -L-iduronidase deficiency and mucopolysaccharidosis I (MPS I) by administering said formulation.

METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF  
RECOMBINANT  $\alpha$ -L-IDURONIDASE

FIELD OF THE INVENTION

5       The present invention is in the field of molecular biology, enzymology, biochemistry and clinical medicine. In particular, the present invention provides a human recombinant  $\alpha$ -L-iduronidase, methods of large-scale production and purification of commercial grade human recombinant  $\alpha$ -L-iduronidase enzyme, and methods to treat certain genetic disorders including  $\alpha$ -L-iduronidase deficiency and  
10   mucopolysaccharidosis I (MPS I).

BACKGROUND OF THE INVENTION

Carbohydrates play a number of important roles in the functioning of living organisms. In addition to their metabolic roles, carbohydrates are structural components  
15   of the human body covalently attached to numerous other entities such as proteins and lipids (called glycoconjugates). For example, human connective tissues and cell membranes comprise proteins, carbohydrates and a proteoglycan matrix. The carbohydrate portion of this proteoglycan matrix provides important properties to the body's structure.

20       A genetic deficiency of the carbohydrate-cleaving, lysosomal enzyme  $\alpha$ -L-iduronidase causes a lysosomal storage disorder known as mucopolysaccharidosis I (MPS I) (Neufeld and Muenzer, pp. 1565-1587, in *The Metabolic Basis of Inherited Disease*, Eds., C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, McGraw-Hill, New York (1989)) In a severe form, MPS I is commonly known as Hurler syndrome and is  
25   associated with multiple problems such as mental retardation, clouding of the cornea, coarsened facial features, cardiac disease, respiratory disease, liver and spleen enlargement, hernias, and joint stiffness. Patients suffering from Hurler syndrome usually die before age 10. In an intermediate form known as Hurler-Scheie syndrome, mental function is generally not severely affected, but physical problems may lead to death by the  
30   teens or twenties. Scheie syndrome is the mildest form of MPS I. It is compatible with a normal life span, but joint stiffness, corneal clouding and heart valve disease cause significant problems.

The frequency of MPS I is estimated to be 1:100,000 according to a British Columbia survey of all newborns (Lowry, *et al.*, *Human Genetics* 85:389-390 (1990)) and 1:70,000 according to an Irish study (Nelson, *Human Genetics* 101:355-358 (1990)). There appears to be no ethnic predilection for this disease. It is likely that worldwide the disease is underdiagnosed either because the patient dies of a complication before the diagnosis is made or because the milder forms of the syndrome may be mistaken for arthritis or missed entirely. Effective newborn screening for MPS I would likely find some previously undetected patients.

Except for a few patients which qualify for bone marrow transplantation, there are no significant therapies available for all MPS I patients. Hobbs, *et al.* (*Lancet* 2: 709-712 (1981)) first reported that bone marrow transplantation successfully treated a Hurler patient. Since that time, clinical studies at several transplant centers have shown improvement in physical disease and slowing or stabilizing of developmental decline if performed early. (Whitley, *et al.*, *Am. J. Med. Genet.* 46: 209-218 (1993); Vellodi, *et al.*, *Arch. Dis. Child.* 76: 92-99 (1997); Peters, *et al.*, *Blood* 91: 2601-2608 (1998); Guffon, *et al.*, *J. Pediatrics* 133: 119-125 (1998)) However, the significant morbidity and mortality, and the need for matched donor marrow, limits the utility of bone marrow transplants. An alternative therapy available to all affected patients would provide an important breakthrough in treating and managing this disease.

Enzyme replacement therapy has been considered a potential therapy for MPS I following the discovery that  $\alpha$ -L-iduronidase can correct the enzymatic defect in Hurler cells in culture, but the development of human therapy has been technically unfeasible until now. In the corrective process, the enzyme containing a mannose-6-phosphate residue is taken up into cells through receptor-mediated endocytosis and transported to the lysosomes where it clears the stored substrates, heparan sulfate and dermatan sulfate. Application of this therapy to humans has previously not been possible due to inadequate sources of  $\alpha$ -L-iduronidase in tissues.

For  $\alpha$ -L-iduronidase enzyme therapy in MPS I, a recombinant source of enzyme has been needed in order to obtain therapeutically sufficient supplies of the enzyme. The cDNA for the canine enzyme was cloned in 1991 (Stoltzfus, *et al.*, *J. Biol. Chem.* 267:6570-6575 (1992)) and for the human enzyme in the same year. (Scott, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88:9695-9699 (1991), Moskowitz, *et al.*, *FASEB J* 6:A77 (1992)).

Following the cloning of cDNA for  $\alpha$ -L-iduronidase, the production of adequate quantities of recombinant  $\alpha$ -L-iduronidase allowed the study of enzyme replacement therapy in canine MPS I. (Kakkis, *et al.*, *Protein Expr. Purif.* 5: 225-232 (1994)) Enzyme replacement studies in the canine MPS I model demonstrated that intravenously-

5 administered recombinant  $\alpha$ -L-iduronidase distributed widely and reduced lysosomal storage from many tissues. (Shull, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 91: 12937-12941 (1994); Kakkis, *et al.*, *Biochem. Mol. Med.* 58: 156-167 (1996))

#### BRIEF SUMMARY OF THE INVENTION

10 In one aspect, the present invention features a method to mass produce human recombinant  $\alpha$ -L-iduronidase in large scale amounts with appropriate purity to enable large scale production for long term patient use of the enzyme therapy. In a broad embodiment, the method comprises the step of transfecting a cDNA encoding for all or part of an  $\alpha$ -L-iduronidase into a cell suitable for the expression thereof. In some

15 embodiments, a cDNA encoding for a complete  $\alpha$ -L-iduronidase is used, preferably a human  $\alpha$ -L-iduronidase. However, in other embodiments, a cDNA encoding for a biologically active fragment or mutein thereof may be used. Specifically, one or more amino acid substitutions may be made while preserving or enhancing the biological activity of the enzyme. In other preferred embodiments, an expression vector is used to

20 transfer the cDNA into a suitable cell or cell line for expression thereof. In one particularly preferred embodiment, the cDNA is transfected into a Chinese hamster ovary cell to create cell line 2.131. In yet other preferred embodiments, the production procedure features one or more of the following characteristics which have demonstrated particularly high production levels: (a) the pH of the cell growth culture may be lowered

25 to about 6.5 to 7.0, preferably to about 6.8 - 7.0 during the production process, (b) as many as 2 to 3.5 culture volumes of the medium may be changed during each 24-hour period by continuous perfusion, (c) oxygen saturation may be optimized to about 40% but may be as high as 80%, (d) macroporous cellulose microcarriers with about 5% serum in the medium initially, may be used to produce cell mass followed by a rapid washout shift

30 to protein-free medium for production, (e) a protein-free or low protein-medium such as a JRH Biosciences PF-CHO product may be optimized to include supplemental amounts of one or more ingredients selected from the group consisting of: glutamate, aspartate,

glycine, ribonucleosides, and deoxyribonucleosides; (f) a stirred tank suspension culture may be perfused in a continuous process to produce iduronidase.

In a second aspect, the present invention provides a transfected cell line, which features the ability to produce  $\alpha$ -L-iduronidase in amounts, which enable using the enzyme therapeutically. In preferred embodiments, the present invention features a  
5 recombinant Chinese hamster ovary cell line such as the 2.131 cell line that stably and reliably produces amounts of  $\alpha$ -L-iduronidase which enable using the enzyme therapeutically. In some preferred embodiments, the cell line may contain more than 1 copy of an expression construct. In even more preferred embodiments, the cell line  
10 expresses recombinant  $\alpha$ -L-iduronidase in amounts of at least 20 micrograms per  $10^7$  cells per day.

In a third aspect, the present invention provides novel vectors suitable to produce  $\alpha$ -L-iduronidase in amounts which enable using the enzyme therapeutically. In preferred embodiments, the present invention features an expression vector comprising a  
15 cytomegalovirus promoter/enhancer element, a 5' intron consisting of a murine C $\alpha$  intron, a cDNA encoding all or a fragment or mutein of an  $\alpha$ -L-iduronidase, and a 3' bovine growth hormone polyadenylation site. Also, preferably the cDNA encoding all or a fragment or mutein of an  $\alpha$ -L-iduronidase is about 2.2 kb in length. This expression vector may be transfected at, for example, a 50 to 1 ratio with any appropriate common  
20 selection vector such as pSV2NEO, to enhance multiple copy insertions. Alternatively, gene amplification may be used to induce multiple copy insertions.

In a fourth aspect, the present invention provides novel  $\alpha$ -L-iduronidase produced in accordance with the methods of the present invention and thereby present in amounts which enable using the enzyme therapeutically. The specific activity of the  $\alpha$ -L-  
25 iduronidase according to the present invention is in excess of 200,000 units per milligram protein. Preferably, it is in excess of about 240,000 units per milligram protein. The molecular weight of the  $\alpha$ -L-iduronidase of the present invention is about 82,000 daltons, about 70,000 daltons being amino acid, and about 12,000 daltons being carbohydrates.

In a fifth aspect, the present invention features a novel method to purify  $\alpha$ -L-  
30 iduronidase. According to a first embodiment, a cell mass may be grown in about 5% serum-containing medium, followed by a switch to a modified protein-free production medium without any significant adaptation to produce a high specific activity starting

material for purification. In one preferred embodiment, a three step column chromatography may be used to purify the enzyme. Such a three step column chromatography may include using a blue sepharose FF, a Cu<sup>++</sup> chelating sepharose chromatography and a phenyl sepharose HP chromatography. In another preferred  
5 embodiment, an acid pH treatment step is used to inactivate potential viruses without harming the enzyme. Concanavalin A-Sepharose, Heparin-Sepharose and Sephacryl 200 columns are removed and Blue-Sepharose and copper chelating columns added to increase the capacity of the large scale purification process, to reduce undesirable leachables inappropriate for long term patient use, and to improve the purity of the  
10 product.

In a sixth aspect, the present invention features novel methods of treating diseases caused all or in part by a deficiency in  $\alpha$ -L-iduronidase. In one embodiment, this method features administering a recombinant  $\alpha$ -L-iduronidase or a biologically active fragment or muterin thereof alone or in combination with a pharmaceutically suitable carrier. In other  
15 embodiments, this method features transferring a nucleic acid encoding all or a part of an  $\alpha$ -L-iduronidase into one or more host cells *in vivo*. Preferred embodiments include optimizing the dosage to the needs of the organism to be treated, preferably mammals or humans, to effectively ameliorate the disease symptoms. In preferred embodiments, the disease is Mucopolysaccharidosis I (MPS I), Hurler syndrome, Hurler-Scheie syndrome or  
20 Scheie syndrome.

In a seventh aspect, the present invention features novel pharmaceutical compositions comprising  $\alpha$ -L-iduronidase useful for treating a disease caused all or in part by a deficiency in  $\alpha$ -L-iduronidase. Such compositions may be suitable for administration in a number of ways such as parenteral, topical, intranasal, inhalation or  
25 oral administration. Within the scope of this aspect are embodiments featuring nucleic acid sequences encoding all or a part of an  $\alpha$ -L-iduronidase, which may be administered *in vivo* into cells, affected with an  $\alpha$ -L-iduronidase deficiency.

#### DESCRIPTION OF THE FIGURES

FIGURE 1 represents the nucleotide and deduced amino acid sequences of cDNA  
30 encoding  $\alpha$ -L-iduronidase (SEQ ID NOS:1 and 2). Nucleotides 1 through 6200 are provided. Amino acids are provided starting with the first methionine in the open reading frame.

FIGURE 2 represents the results from SDS-PAGE runs of eluate obtained according to the procedures as described below. The top panel shows the SDS-PAGE results of purified  $\alpha$ -L-iduronidase (3 micrograms) and contaminants from the production/purification scheme disclosed in Kakkis, *et al.*, *Protein Expr. Purif.* 5: 225-232 (1994). In the bottom panel, SDS-PAGE results of purified  $\alpha$ -L-iduronidase with contaminants from an unpublished prior production/purification process (U.S. Patent Application Serial Nos. 09/078,209 and 09/170,977) referred to as the Carson method in Lanes 2 (7.5 microgram  $\alpha$ -L-iduronidase) and Lane 3 (5.0 microgram  $\alpha$ -L-iduronidase) are compared to that of the production/purification process of the present invention referred to as the Galli Process (Lane 4 5 micrograms  $\alpha$ -L-iduronidase). Lane 1 contains the molecular weight marker. FIGURE 2 shows that the Galli production/purification method of the present invention yields a highly purified  $\alpha$ -L-iduronidase product with fewer contaminants in comparison with prior production/purification schemes.

FIGURE 3 demonstrates the  $\alpha$ -iduronidase production level over a 30-day period, during which time cells are switched at day 5 from a serum – containing medium to a serum-free medium.  $\alpha$ -Iduronidase production was characterized by: (1) absence of a need for adaptation when cells are switched from serum-containing to serum-free medium at 100200 (top and bottom panels) with an uninterrupted increase in productivity (top panel); (2) a high level of production in excess of 4 mg per liter (1000 per mL) in a protein-free medium (bottom panel); and (3) a boost in  $\alpha$ -iduronidase production with butyrate induction events (bottom panel).

FIGURE 4 demonstrates a decrease in liver volume during enzyme therapy in MPS I patients.

FIGURE 5 demonstrates urinary GAG excretion during enzyme therapy.

FIGURE 6 demonstrates elbow and knee extension in HAC002 during enzyme therapy.

FIGURE 7 demonstrates shoulder flexion to 104 weeks in four patients with the most restriction during enzyme therapy.

FIGURE 8 demonstrates improvement in sleep apnea before and after six weeks of therapy.

FIGURE 9 demonstrates the improvement in apneas and hypopneas during sleep with enzyme therapy in each individual patient.

FIGURE 10 demonstrates the improvement in pulmonary function tests before and after 12 and 52 weeks of enzyme therapy in one patient.

FIGURE 11 demonstrates increased height growth velocity with enzyme therapy.

FIGURE 12 shows the degree of contamination by Chinese Hamster Ovary

5 Protein (CHOP) and degree of purity of  $\alpha$ -L-iduronidase, produced by (1) the Carson method, an unpublished prior production/purification process (U.S. Patent Application Serial Nos. 09/078,209 and 09/170,977 and (2) the Galli method, the production/purification process of the present invention. Thus, FIGURE 12 shows that  $\alpha$ -L-iduronidase produced and purified by the Galli method has a higher degree of purity  
10 and lower degree of CHOP contamination in comparison to that of the Carson method.

FIGURE 13 shows a comparison of  $\alpha$ -L-iduronidase produced by the Galli method versus the Carson method. On the left side of the Figure, results from a Western Blot show that the Galli material (left side, column 2) comprise fewer contaminating protein bands (between 48 kDa and 17 kDa) in comparison with the Carson material (left side,  
15 column 3). On the right side of the Figure, results from an SDS-PAGE silver stain show the absence of a band at the 62 kDa in the Galli material (column 2) in comparison to the presence of such a band in the Carson material (column 3).

#### DETAILED DESCRIPTION OF THE INVENTION

20 In one aspect, the present invention features a method to produce  $\alpha$ -L-iduronidase in amounts which enable using the enzyme therapeutically. In general, the method features transforming a suitable cell line with the cDNA encoding for all of  $\alpha$ -L-iduronidase or a biologically active fragment or mutein thereof. Those of skill in the art may prepare expression constructs other than those expressly described herein for optimal  
25 production of  $\alpha$ -L-iduronidase in suitable cell lines transfected therewith. Moreover, skilled artisans may easily design fragments of cDNA encoding biologically active fragments and muteins of the naturally occurring  $\alpha$ -L-iduronidase which possess the same or similar biological activity to the naturally occurring full-length enzyme.

To create a recombinant source for  $\alpha$ -L-iduronidase, a large series of expression  
30 vectors may be constructed and tested for expression of a  $\alpha$ -L-iduronidase cDNA. Based on transient transfection experiments, as well as stable transfections, an expression construct may be identified that provides a particularly high level of expression. In one



embodiment of the present invention, a Chinese hamster cell line 2.131 developed by transfection of the  $\alpha$ -L-iduronidase expression construct and selection for a high expression clone provides particularly high level expression. Such a Chinese hamster cell line according to this embodiment of the present invention may secrete about 5,000 to  
5 7,000 fold more  $\alpha$ -L-iduronidase than normal. The  $\alpha$ -L-iduronidase produced thereby may be properly processed, taken up into cells with high affinity and is corrective for  $\alpha$ -L-iduronidase deficient cells, such as those from patients suffering from Hurler's Syndrome.

The method for producing  $\alpha$ -L-iduronidase in amounts that enable using the enzyme therapeutically features a production process specifically designed to mass  
10 produce commercial grade enzyme, wherein the quality of the enzyme has been deemed acceptable for administration to humans by regulatory authorities of various countries. The large scale production of commercial grade enzyme necessitates modifications of the cell culture scale, microcarrier systems, and purification scheme. In preferred embodiments, the cell culture scale is increased from 45 liters to 110 liters or more, with a  
15 change to continuous perfusion. The increase in scale is necessary to produce sufficient material for potential large scale production for long term patient use. According to preferred embodiments of such a process, microcarriers are used as a low cost scalable surface on which to grow adherent cells. In particularly preferred embodiments, such microcarriers are macroporous and are specifically composed of modified carbohydrates  
20 such as cellulose, e.g., Cytopore beads manufactured by Pharmacia. Macroporous cellulose microcarriers allow improved cell attachment and provide a larger surface area for attachment, which is expected to yield an increased cell density during the culture process. Higher cell densities are expected to increase productivity. In preferred embodiments, heparin-Sepharose and Sephacryl 200 columns are replaced with Blue-  
25 Sepharose and Copper chelating columns to increase the capacity of the large scale purification process and to improve the purity of the product. In a particularly preferred embodiment, the copper chelating column is used to reduce Chinese hamster ovary cell protein contaminants to very low levels appropriate for large scale distribution. Using embodiments of the present method featuring modifications and induction described  
30 below, approximately 15 mg per liter of culture per day, or more at peak culturing density can be produced starting with a 110 liter culture system.

According to other preferred embodiments of the method for producing  $\alpha$ -L-iduronidase according to the present invention, a culture system is optimized. In a first embodiment, the culture pH is lowered to about 6.5 to 7.0, preferably to about 6.7-7.0 during the production process. One advantage of such a pH is to enhance accumulation of lysosomal enzymes that are more stable at acidic pH. In a second embodiment, as many as 2 to 3.5 culture volumes of the medium may be changed during each 24-hour period by continuous perfusion. One advantage of this procedure is to enhance the secretion rate of recombinant  $\alpha$ -L-iduronidase and to capture more active enzyme. In a third embodiment, oxygen saturation is optimized at about 40%. In a fourth embodiment, macroporous microcarriers with about 5% serum initially in the medium, are used to produce a cell mass followed by a rapid washout shift to a protein-free medium for production (FIGURE 3). In a fifth embodiment, a protein-free growth medium, such as a JRH Biosciences PF-CHO product, may be optimized to include supplemental amounts of one or more ingredients selected from the group consisting of: glutamate, aspartate, glycine, ribonucleosides and deoxyribonucleosides. In a sixth embodiment, as many as 2 to 3.5 culture volumes of the medium may be changed during each 24-hour period by continuous perfusion. Such an induction process may provide about a two-fold increase in production without significantly altering post-translational processing.

Particularly preferred embodiments of the method for producing  $\alpha$ -L-iduronidase according to the present invention feature one, more than one, or all of the optimizations described herein and may be employed as described in more detail below. The production method of the present invention may, therefore, provide a production culture process having the following features:

1. A microcarrier based culture using macroporous microcarrier beads made of modified cellulose or an equivalent thereof is preferably used in large scale culture flasks with overhead stirring or an equivalent thereof. Attachment of cells to these beads may be achieved by culture in a 5% fetal bovine serum may be added to DME/F12 1:1 or a protein-free medium modified with ingredients including ribonucleosides, deoxyribonucleosides, pyruvate, non-essential amino acids, and HEPES. After about 3-6 days in this medium, a washout procedure is begun in which protein-free medium replaces the serum-containing medium at an increasing perfusion rate dependent on the glucose content and culture condition. Subsequently, and throughout the entire remaining culture

period, the cells are cultivated in a protein-free medium. The use of a protein-free medium in enzyme production is beneficial in reducing the exposure risk of bovine spongiform encephalopathy (BSE) and other infectious biologic agents such as viruses to patients being treated with the enzyme, wherein the risk of BSE or other harmful agents is dependent on the amount of potential serum exposure. In prior published studies, the carriers used to grow the cells were bovine gelatin microcarriers, used at 1 gram per liter or 100 times the product concentration. Leaching of 1% of the gelatin protein from the microcarriers would represent a relative 100% contamination and thereby contribute to the risk of BSE. Thus, new carriers are either dextran or cellulose-based and consist of carbohydrates, and not animal-derived materials.

FIGURE 3 shows that the cells are grown to a density in 5% serum containing medium and then switched without any adaptation to a protein-free medium. FIGURE 3 specifically shows that: 1) Cells survive and continue to produce iduronidase when shifted without adaptation. In contrast, other studies would suggest that adaptation to a protein-free medium is necessary. In the method of the present invention, enzyme production continues at levels comparable to serum containing medium. 2)  $\alpha$ -L-Iduronidase produced in a protein-free medium retains a level of production in excess of 4 mg per liter or 1,000 units per ml. 3)  $\alpha$ -L-Iduronidase produced in a protein-free medium has high uptake indicating that the shift in medium and, hence, a shift in carbohydrates being fed to cells, does not adversely affect the high uptake character of the enzyme. Eight lots of  $\alpha$ -L-iduronidase have been produced and released in this manner with an uptake half maximal value of less than 2nM in all lots.

2. The culture conditions are preferably maintained at a dissolved oxygen of 40% of air saturation at a pH of about 6.8-7.0 and at a temperature of about 35-37° C. This may be achieved using a control unit, monitoring unit and appropriate probes such as those produced by Applikon® or Mettler®. However, skilled artisans will readily appreciate that this can easily be achieved by equivalent control systems produced by other manufacturers. An air saturation of about 40% results in improved  $\alpha$ -L-iduronidase secretion though up to 80% air saturation may be used. However, further increases in oxygen to, for example, 90% air saturation, do not provide significantly enhanced secretion over 80% air saturation. The dissolved oxygen may be supplied by intermittent or continuous oxygen sparging using a 5 micron stainless steel or larger opening sparger,

or equivalent thereof. A pH of about 6.8-7.0 is optimal for the accumulation of the  $\alpha$ -L-iduronidase enzyme. The enzyme is particularly unstable at pHs above about 7.0. Below a pH of about 6.7, the secretion rate may decrease, particularly below a pH of about 6.5. The culture is therefore maintained optimally between a pH of about 6.8-7.0 .

5           3.     The production culture medium may be a modified form of the commercially available proprietary medium from JRH Biosciences called Excell PF CHO. This medium supports levels of secretion equivalent to that of serum using a cell line such as the 2.131 cell line. It may be preferably modified to include an acidic pH of about 6.8-7.0 ( $\pm 0.1$ ), and buffered with HEPES at 7.5 mM or 15 mM. The medium may  
10   contain 0.05 to 0.1% of Pluronic F-68 (BASF), a non-ionic surfactant or an equivalent thereof which features the advantage of protecting cells from shear forces associated with sparging. The medium may further contain a proprietary supplement that is important in increasing the productivity of the medium over other protein-free media that are presently available. Those skilled in the art will readily understand that the choice of culture  
15   medium may be optimized continually according to particular commercial embodiments available at particular points in time. Such changes encompass no more than routine experimentation and are intended to be within the scope of the present invention.

          4.     The production medium may be analyzed using an amino acid analyzer comparing spent medium with starting medium. Such analyses have demonstrated that  
20   the 2.131 cell line depletes a standard PF CHO medium of glycine, glutamate and aspartate to a level of around 10% of the starting concentration. Supplementation of these amino acids to higher levels may result in enhanced culture density and productivity that may lead to a 2-3 fold higher production than at baseline. Skilled artisans will appreciate that other cell lines within the scope of the present invention may be equally useful for  
25   producing  $\alpha$ -L-iduronidase according to the present method. Hence, more or less supplemental nutrients may be required to optimize the medium. Such optimizations are intended to be within the scope of the present invention and may be practiced without undue experimentation.

          5.     The medium may be supplemented with the four ribonucleosides and four  
30   deoxyribonucleosides each at about 10 mg/liter to support the dihydrofolate reductase deficient cell line 2.131. Skilled artisans will appreciate that other cell lines within the scope of the present invention may be equally useful for producing  $\alpha$ -L-iduronidase

according to the present method. Hence, more or less ribonucleosides and deoxyribonucleosides may be required to optimize the medium, and alternative sources of purines and pyrimidines for nucleic acid synthesis may be used such as hypoxanthine and thymidine. Such optimizations are intended within the scope of the present invention and  
5 may be practiced without undue experimentation.

6. After reaching confluence at about 3-6 days of culture, an increasing rate of continuous perfusion is initiated. A change of medium may be accomplished, for example, using a slant feed tube constructed and positioned to allow the uptake of medium without removal of the microcarriers even while the culture is stirred. By  
10 pumping out medium through the slant feed tube, microcarriers settle within the body of the tube inside the culture and are not removed from the culture during the change on medium. In this manner, the microcarriers with the cell mass are separated from supernatant containing the enzyme.

7. The rapid and frequent turnover of the medium has been shown by  
15 productivity studies to result in improved overall collection of enzyme from the cell culture. Less turnover of medium results in less total production of enzyme on a daily basis. Using the perfusion of 2-3.5 culture volumes per day, the cells may be maintained in excellent condition with high degrees of viability and a high level of productivity.

8. Production of  $\alpha$ -L-iduronidase may be enhanced by the use of sodium  
20 butyrate induction of gene expression (FIGURE 3). Twenty lots of  $\alpha$ -L-iduronidase were produced using butyrate induction at 2mM concentration with 2/3 washout every 12 hours after induction and reinduction every 48 hours for a 21-day production period. In Figure 3, the vertical arrows at the bottom indicate butyrate induction events. Each induction triggered a boost in  $\alpha$ -L-iduronidase concentration in the medium.

25 Systematic studies of a 2.131 cell line demonstrated that about 2 mM butyrate can be applied and result in about a two-fold or greater induction of enzyme production with minimal effects on carbohydrate processing. Lower levels of butyrate have not been shown to induce as well, and substantially higher levels may result in higher induction, but declining affinity of the produced enzyme for cells from patients suffering from  $\alpha$ -L-  
30 iduronidase deficiency. Butyrate induction performed *in vitro* at 2mM for 24 hours or 5 mM, a more commonly used concentration resulted in uptakes in excess of 3 nM or 40 U/ml, or an average of three times the value observed in production lots. In addition,

commonly used times of 24 hours or more and concentration of 5 mM were toxic to  $\alpha$ -L-iduronidase producing cells and resulted in detachment and loss of cell mass.

Results suggest that two-fold or greater induction results in less processing of the carbohydrates and less phosphate addition to the enzyme, as well as increasing toxicity.

5 With respect to carbohydrate processing and the addition of phosphate groups, the importance of mannose-6-phosphate in enzyme replacement therapy is demonstrated by the observations that removal of the phosphate of two lysosomal enzymes, glucosidase and galactosamine 4-sulfatase leads to decreased uptake (Van der Ploeg, *et al.*, *J. Clin. Invest.* 87: 513-518 (1991); Crawley, *et al.*, *J. Clin. Invest.* 97: 1864-1873 (1996)). In  
10 addition, enzyme with low phosphate (Van Hovè, *et al.*, *Proc. Natl. Acad. Sci. USA* 93: 65-70 (1996) requires 1,000 units per ml for uptake experiments (nearly 100 times used for iduronidase) and effective doses in animal models require 14 mg/kg, or 28 times the dose used with high phosphate containing iduronidase (Kikuchi, *et al.*, *J. Clin. Invest.* 101: 827-833 (1998)).

15 One particularly preferred aspect of the invention method uses 2 mM butyrate addition every 48 hours to the culture system. This embodiment results in about a two-fold induction of enzyme production using this method without significant effect on the uptake affinity of the enzyme (K-uptake of less than 30 U/ml or 2.0 mM).

In a second aspect, the present invention provides a transfected cell line, which  
20 possesses the unique ability to produce  $\alpha$ -L-iduronidase in amounts, which enable using the enzyme therapeutically. In preferred embodiments, the present invention features a recombinant Chinese hamster ovary cell line such as the 2.131 cell line that stably and reliably produces amounts of  $\alpha$ -L-iduronidase. In preferred embodiments, the cell line may contain more than 1 copy of an expression construct comprising a CMV promoter, a  
25 C $\alpha$  intron, a human  $\alpha$ -L-iduronidase cDNA, and a bovine growth hormone polyadenylation sequence. In even more preferred embodiments, the cell line expresses  $\alpha$ -L-iduronidase at amounts of at least about 20-40 micrograms per  $10^7$  cells per day in a properly processed, high uptake form appropriate for enzyme replacement therapy. According to preferred embodiments of this aspect of the invention, the transfected cell  
30 line adapted to produce  $\alpha$ -L-iduronidase in amounts which enable using the enzyme therapeutically, possesses one or more of the following features:

1. The cell line of preferred embodiments is derived from a parent cell line wherein the cells are passaged in culture until they have acquired a smaller size and more rapid growth rate and until they readily attach to substrates.

2. The cell line of preferred embodiments is transfected with an expression vector  
5 containing the cytomegalovirus promoter/enhancer element, a 5' intron consisting of the murine C $\alpha$  intron between exons 2 and 3, a human cDNA of about 2.2 kb in length, and a 3' bovine growth hormone polyadenylation site. This expression vector may be transfected at, for example, a 50 to 1 ratio with any appropriate common selection vector such as pSV2NEO. The selection vector pSV2NEO in turn confers G418 resistance on  
10 successfully transfected cells. In particularly preferred embodiments, a ratio of about 50 to 1 is used since this ratio enhances the acquisition of multiple copy number inserts. According to one embodiment wherein the Chinese hamster ovary cell line 2.131 is provided, there is at least 1 copy of the expression vector for  $\alpha$ -L-iduronidase. Such a cell line has demonstrated the ability to produce large quantities of human  $\alpha$ -L-iduronidase  
15 (minimum 20 micrograms per 10 million cells per day). Particularly preferred embodiments such as the 2.131 cell line possess the ability to produce properly processed enzyme that contains N-linked oligosaccharides containing high mannose chains modified with phosphate at the 6 position in sufficient quantity to produce an enzyme with high affinity (K<sub>m</sub>-uptake of less than 3 nM).

20 3. The enzyme produced from the cell lines of the present invention such as a Chinese hamster ovary cell line 2.131 is rapidly assimilated into cells, eliminates glycosaminoglycan storage and has a half-life of about 5 days in cells from patients suffering from  $\alpha$ -L-iduronidase deficiency.

4. The cell line of preferred embodiments such as a 2.131 cell line adapts to  
25 large scale culture and stably produces human  $\alpha$ -L-iduronidase under these conditions. The cells of preferred embodiments are able to grow and secrete  $\alpha$ -L-iduronidase at the acid pH of about 6.6 to 7.0 at which enhanced accumulation of  $\alpha$ -L-iduronidase can occur.

5. Particularly preferred embodiments of the cell line according to the  
30 invention, such as a 2.131 cell line are able to secrete human  $\alpha$ -L-iduronidase at levels exceeding 2,000 units per ml (8 micrograms per ml) harvested twice per day or exceeding 15 mg per liter of culture per day using a specially formulated protein-free medium.

In a third aspect, the present invention provides novel vectors suitable to produce  $\alpha$ -L-iduronidase in amounts which enable using the enzyme therapeutically. The production of adequate quantities of recombinant  $\alpha$ -L-iduronidase is a critical prerequisite for studies on the structure of the enzyme as well as for enzyme replacement therapy. The cell lines according to the present invention permit the production of significant quantities of recombinant  $\alpha$ -L-iduronidase that is appropriately processed for uptake.

Overexpression in Chinese hamster ovary (CHO) cells has been described for three other lysosomal enzymes,  $\alpha$ -galactosidase (Ioannou, *et al.*, *J Cell. Biol.* 119:1137-1150 (1992)), iduronate 2-sulfatase (Bielicki, *et al.*, *Biochem. J.* 289: 241-246 (1993)), and N-acetylgalactosamine 4 -sulfatase (Amson, *et al.*, *Biochem. J.* 284:789-794 (1992)), using a variety of promoters and, in one case, amplification. The present invention features a dihydrofolate reductase-deficient CHO cell line, but according to preferred embodiments of the invention amplification is unnecessary. Additionally, the present invention provides a high level of expression of the human  $\alpha$ -L-iduronidase using the CMV immediate early gene promoter/enhancer.

The present invention features in preferred embodiments, an expression vector comprising a cytomegalovirus promoter/enhancer element, a 5' intron consisting of the murine C $\alpha$  intron derived from the murine long chain immunoglobulin C $\alpha$  gene between exons 2 and 3, a human cDNA of about 2.2 kb in length, and a 3' bovine growth hormone polyadenylation site. This expression vector may be transfected at, for example, a 50 to 1 ratio with any appropriate common selection vector such as pSV2NEO. The selection vector such as pSV2NEO in turn confers G418 resistance on successfully transfected cells. In particularly preferred embodiments, a ratio of about 50 to 1 expression vector to selection vector is used since this ratio enhances the acquisition of multiple copy number inserts. According to one embodiment wherein the Chinese hamster ovary cell line 2.131 is provided, there are approximately 10 copies of the expression vector for  $\alpha$ -L-iduronidase. Such an expression construct has demonstrated the ability to produce large quantities of human  $\alpha$ -L-iduronidase (minimum 20 micrograms per 10 million cells per day) in a suitable cell line such as a Chinese hamster ovary cell line 2.131.

In a fourth aspect, the present invention provides novel  $\alpha$ -L-iduronidase produced in accordance with the methods of the present invention and thereby present in amounts that enable using the enzyme therapeutically. The methods of the present invention



produce a substantially pure  $\alpha$ -L-iduronidase that is properly processed and in high uptake form, appropriate for enzyme replacement therapy and effective in therapy *in vivo*.

The specific activity of the  $\alpha$ -L-iduronidase according to the present invention is in excess of about 200,000 units per milligram protein. Preferably, it is in excess of about  
5 240,000 units per milligram protein using the original assay methods for activity and protein concentration. A novel validated assay for the same enzyme with units expressed as micromoles per min demonstrates an activity of 100 units/ml (range of 70-130) and a protein concentration by absorbance at 280 nM of 0.7 mg/ml (0.6-0.8) with an average specific activity of 143 units per mg. The molecular weight of the full length  $\alpha$ -L-  
10 iduronidase of the present invention is about 82,000 daltons comprising about 70,000 daltons of amino acids and 12,000 daltons of carbohydrates. The recombinant enzyme of the present invention is endocytosed even more efficiently than has been previously reported for a partially purified preparation of urinary enzyme. The recombinant enzyme according to the present invention is effective in reducing the accumulation of radioactive  
15 S-labeled GAG in  $\alpha$ -L-iduronidase-deficient fibroblasts, indicating that it is transported to lysosomes, the site of GAG storage. The remarkably low concentration of  $\alpha$ -L-iduronidase needed for such correction (half-maximal correction at 0.7 pM) may be very important for the success of enzyme replacement therapy.

The human cDNA of  $\alpha$ -L-iduronidase predicts a protein of 653 amino acids and  
20 an expected molecular weight of 70,000 daltons after signal peptide cleavage. Amino acid sequencing reveals alanine 26 at the N-terminus giving an expected protein of 629 amino acids. Human recombinant  $\alpha$ -L-iduronidase has a Histidine at position 8 of the mature protein. The predicted protein sequence comprises six potential N-linked oligosaccharide modification sites. All of these may be modified in the recombinant  
25 protein. The third and sixth sites have been demonstrated to contain one or more mannose 6-phosphate residues responsible for high affinity uptake into cells. The following peptide corresponds to Amino Acids 26-45 of Human Recombinant  $\alpha$ -L-iduronidase with an N-terminus alanine and the following sequence:

ala-glu-ala-pro-his-leu-val-his-val-asp-ala-ala-arg-ala-leu-trp-pro-leu-arg-arg  
30 (part of SEQ ID NO:2)

The overexpression of the  $\alpha$ -L-iduronidase of the present invention does not result in generalized secretion of other lysosomal enzymes that are dependent on mannose-6-P

targeting. The secreted recombinant  $\alpha$ -L-iduronidase is similar to normal secreted enzyme in many respects. Its molecular size, found in various determinations to be 77, 82, 84, and 89 kDa, is comparable to 87 kDa, found for urinary corrective factor (Barton *et al.*, *J. Biol. Chem.* 246: 7773-7779 (1971)), and to 76 kDa and 82 kDa, found for enzyme secreted by cultured human fibroblasts (Myerowitz, *et al.*, *J. Biol. Chem.* 256: 3044-3048 (1991); Taylor, *et al.*, *Biochem. J* 274:263-268 (1991)). The differences within and between the studies are attributed to imprecision of the measurements. The pattern of intracellular processing of the recombinant enzyme, a slow decrease in molecular size and the eventual appearance of an additional band smaller by 9 kDa is the same as for the human fibroblast enzyme. This faster band arises by proteolytic cleavage of 80 N-terminal amino acids.

In a fifth aspect, the present invention features a novel method to purify  $\alpha$ -L-iduronidase. The U.S. Food and Drug Administration has issued recommendations for assembling chemical and technological data currently considered appropriate for an enzyme preparation, including guidelines regarding the purity of enzyme preparations (Enzyme Preparations: Chemistry Recommendations for Food Additive and GRAS [Generally Recommended As Safe] Affirmation Petitions, Version 1.1, January 23, 1993; U.S. Food and Drug Administration, Center For Food Safety and Applied Nutrition, Office of Premarket Approval, Chemistry Review Branch). Various studies have shown that impurities, such as anticomplement activity, in protein preparations, including immunoglobulin preparations, may be associated with the development of allergic and anaphylactic reactions (Lundblad, *et al.*, *Rev. Infect. Dis.* 8 (Suppl. 4):S382-90 (1986); Scheiermann and Kuwert, *Dev. Biol. Stand.* 44:165-171 (1979)). Furthermore, impurities may be associated with unwanted biological activities and interference with desired therapeutic effects. Thus, enhanced purity of protein preparations would contribute to greater efficacy of the therapeutic protein (Ueshima, *et al.*, *J. Clin. Hosp. Pharm.* 10(2): 193-202 (1985); Ehrlich, *et al.*, *Clin. Chem.* 34(9): 1681-8 (1988)).

The relationship between enzyme purity and immunogenicity is demonstrated in Studies 1 (Example 5) and 2 (Example 6). Two types of immune reactions, urticaria and complement activation (indicated by laboratory analysis), were documented during enzyme infusion and may be associated with enzyme therapy. In the Phase I study (Example 5), the purity of recombinant human  $\alpha$ -L-iduronidase was between 96% to

98%. In the Phase III study (Example 6), recombinant human  $\alpha$ -L-iduronidase was purified to greater than 99%. Figures 12 and 13 compare the degree of contamination by the other proteins, such as Chinese Hamster Ovary Protein, and the purity of the recombinant human  $\alpha$ -L-iduronidase produced by the previous Carson and current Galli methods. The results show that the recombinant human  $\alpha$ -L-iduronidase purified according to the Galli method has fewer protein contaminants than enzyme produced by the Carson method. In the Phase I study using enzyme purified to 96-98%, five patients developed urticaria and evidence of complement activation was observed in four patients. In the Phase III study using enzyme purified to greater than 99%, none of the enzyme-treated patients developed urticaria. Although all enzyme – treated patients seroconverted in immunogenicity testing for IgG, seroconversion did not result in increased infusion-associated reactions or other adverse events. In patients tested for IgE, results were negative. The relationship between purity and immunogenicity is even more evident in the animal studies described in Example 3, wherein the purity of the recombinant human  $\alpha$ -L-iduronidase was equal or less than or about 95%. In the animal studies, all MPS I dogs and most MPS I cats receiving enzyme treatment developed antibodies, including IgG antibodies of the complement-activating type, a phenomenon observed in 13 % of alglucerase-treated Gaucher patients. One MPS I dog also developed proteinuria thought to be related to immune complex disease. These studies suggest that an increased level of enzyme purity is associated with a lower frequency of immune-related adverse side effects and hence with greater safety and efficacy of enzyme therapy.

In preferred embodiments, the present invention features a method to purify recombinant  $\alpha$ -L-iduronidase that has been optimized to produce a rapid and efficient purification with validatable chromatography resins and easy load, wash and elute operation. The method of purifying  $\alpha$ -L-iduronidase of the present invention involves a series of column chromatography steps, which allow the high yield purification of enzyme from protein-free production medium. Specifically, Concanavalin A-Sepharose, Heparin-Sepharose and Sephacryl 200 columns were replaced with Blue-Sepharose and Copper chelating columns to increase the capacity of a large-scale purification process, to reduce leachables and to improve the purity of the product. Concanavalin A lectin is often used to bind enzyme in an initial purification step in the prior published study, and is a protein lectin derived from plants. Concanavalin A is known to leach from columns and

contaminate lysosomal enzyme preparations. Such leaching could cause activation of T cells in treated patients and hence is deemed inappropriate for human administration (Furbish, *et al.*, *Proc. Natl. Acad. Sci. USA* 74: 3560-3563 (1977)). Thus, the use of Concanavalin A is avoided in the present purification scheme. In a prior study, the human liver  $\alpha$ -L-iduronidase could not be recovered from phenyl columns without high concentrations of detergent (1% Triton X100) denaturation. Hence, a phenyl column was not used in a published purification scheme of this enzyme (Clements, *et al.*, *Eur. J. Biochem.* 152: 21-28 (1985)). The endogenous human liver enzyme is highly modified within the lysosomes by hydrolases, which remove sialic acid and phosphate residues, and proteases, which nick the enzyme. In contrast, the overexpression of recombinant  $\alpha$ -L-iduronidase causes 50% of the enzyme to be secreted rather than transported to the lysosome (Zhao, *et al.*, *J. Biol. Chem.* 272: 22758-22765 (1997)). Hence, recombinant iduronidase will have a full array of sialic acid and phosphate residues, which lead to a higher degree of water solubility and lower affinity to the phenyl column. The increased hydrophilicity allows the enzyme to be eluted under non-denaturing conditions using the low salt solutions of around 150-700 mM NaCl. This feature of the recombinant enzyme allows it to be purified in large scale without the use of detergents.


Recombinant  $\alpha$ -L-iduronidase over-expressed in a Chinese Hamster Ovary (CHO) cell line, has been purified to near homogeneity following a 3-step column chromatography process. The first column involves an affinity chromatography step using Blue Sepharose 6 FF. The Blue Sepharose 6 FF eluate is then further purified by another affinity chromatography step using  $\text{Cu}^{++}$  Chelating Sepharose FF. The final polish of the highly purified enzyme is achieved by hydrophobic interaction chromatography using Phenyl Sepharose High Performance (HP). The over-all yield ranges from 45 to 55 percent and the purity of the final product is > 99%. The process is robust, reproducible, and scalable for large-scale manufacturing. The purified enzyme has been characterized with respect to its enzymatic activity using a fluorescence-based substrate, and its functional uptake by fibroblast cells. The enzyme has also been characterized for substrate specificity, carbohydrate profiles, and isoelectric focusing (IEF) profiles.

Particularly preferred embodiments of the method for purifying  $\alpha$ -L-iduronidase according to the present invention feature more than one or all of the optimizations

according to the following particular embodiments. The purification method of the present invention may therefore provide a purified  $\alpha$ -L-iduronidase having the characteristics described herein.

#### Outline of the $\alpha$ -L-Iduronidase Purification Process

5



1. pH Adjustment/Filtration: The pH of filtered harvest fluid (HF) is adjusted to 5.3 with 1 M  $\text{H}_3\text{PO}_4$  and then filtered through a 0.45  $\mu$  filter (e.g. Sartoclean, Sartorius).

2. Blue Sepharose FF chromatography: This affinity chromatography step serves to capture iduronidase to reduce the volume and to purify iduronidase by approximately seven to ten fold.

Loading capacity: 4 mg/ml (total protein per ml of resin)

	Equilibration buffer:	10 mM NaPO <sub>4</sub> , pH 5.3
	Wash buffer:	400 mM NaCl, 10 mM NaPO <sub>4</sub> , pH 5.3
	Elution buffer:	0.8 M NaCl, 10 mM NaPO <sub>4</sub> , pH 5.3
	Regeneration buffer:	2 M NaCl, 10 mM NaPO <sub>4</sub> , pH 5.3
5	Fold of purification:	7-10
	Yield:	70-85%

3. Cu<sup>++</sup> Chelating Sepharose FF chromatography: The Cu<sup>++</sup> Chelating affinity chromatography step is very effective for removing some contaminating CHO proteins. The inclusion of 10% glycerol in all the buffers seems to be crucial for the quantitative recovery of iduronidase.

	Loading capacity:	2 mg/ml
	Equilibration buffer:	1 M NaCl, 25 mM NaAc, pH 6.0, 10% Glycerol
	Wash buffer:	1 M NaCl, 25 mM NaAc, pH 4.0, 10% Glycerol
	Elution buffer:	1 M NaCl, 25 mM NaAc, pH 3.7, 10% Glycerol
15	Regeneration buffer:	1 M NaCl, 50 mM EDTA, pH 8.0
	Fold of purification:	2-5
	Yield:	80%

4. Phenyl Sephrose HP chromatography: Phenyl Sephrose is used as the last step to further purify the product as well as to reduce residual leached Cibacron blue dye and Cu<sup>++</sup> ion carried over from previous columns.

	Loading capacity:	1 mg/ml
	Equilibration buffer:	2 M NaCl, 10 mM NaPO <sub>4</sub> , pH 5.7
	Wash buffer:	1.5 M NaCl, 10 mM NaPO <sub>4</sub> , pH 5.7
	Elution buffer:	0.7 M NaCl, 10 mM NaPO <sub>4</sub> , pH 5.7
25	Regeneration buffer:	0 M NaCl, 10 mM NaPO <sub>4</sub> , pH 5.7
	Fold of purification:	1.5
	Yield:	90%

5. Ultrafiltration (UF)/Diafiltration (DF)/Final formulation: The purified iduronidase is concentrated and diafiltered to a final concentration of 1 mg/ml in formulation buffer (150 mM NaCl, 100 mM NaPO<sub>4</sub>, pH 5.8) using a tangential flow filtration (TFF) system (e.g. Sartoclon Slice from Sartorius). The enzyme is then sterilized

by filtering through a 0.2-micron filter (e.g., cellulose acetate or polysulfone) and filled into sterile vials.

6. Characterization of Purified Iduronidase: Analysis of enzyme purity using SDS-PAGE stained with Coomassie Blue or Silver and Western blot analysis. Analysis of enzymatic activity using 4MU-sulfate as substrate. Analysis of functional uptake using fibroblast cell assay. Analysis of carbohydrates by FACE. Analysis of IEF profiles.

Enzyme purified in this manner has been shown to contain mannose-6-phosphate residues of sufficient quantity at positions 3 and 6 of the N-linked sugars to give the enzyme uptake affinity of less than 30 units per ml (less than 2 nM) enzyme. The enzyme is substantially corrective for glycosaminoglycan storage disorders caused by iduronidase deficiency and has a half-life inside cells of approximately 5 days.

Prior  $\alpha$ -L-iduronidase purification schemes (Kakkis, *et al.*, *Protein Expr. Purif.* 5: 225-232 (1994); Kakkis, *et al.*, *Biochem. Mol. Med.* 58: 156-167 (1996); U.S. Patent Application Nos. 09/078,209 and 09/170,977) produced degrees of purity between 90% and less than 99%, which is not optimal for long-term human administration (See FIGURE 12). (These and all other U.S. patents herein are specifically incorporated herein by reference in their entirety.) Treatment with human recombinant  $\alpha$ -L-iduronidase with a minimum purity of 97% was associated with some clinical reactions, specifically hives in 5 patients, and complement activation in 4 patients. All patients demonstrated a reaction to a protein that is a trace contaminant to the  $\alpha$ -L-iduronidase. (FIGURE 2) Because this protein exists in both the final product and in the serum-free blank CHO cell line supernatant, the extraneous protein most likely originates from the CHO cell. The common proteins that appear to be activating the clinical allergic response are approximately 60kDaltons and 50kDaltons respectively, which are too small to be recombinant human iduronidase. Four patients developed an immune reaction to  $\alpha$ -L-iduronidase at least transiently as well as to the Chinese hamster ovary cell host proteins. It is clear that even though the enzyme used to treat patients is highly purified, the degree of purification is important in reducing the immune response to contaminants. FIGURE 2 (SDS-PAGE), FIGURE 12 (CHOP assay), and FIGURE 13 (Western Blot, Silver Stain) demonstrate that  $\alpha$ -L-iduronidase produced and purified by the production/purification scheme of the present invention has a higher degree of purity and lower degree of CHOP contamination in comparison to that of prior methods of production/purification. Thus, a

greater than 97% purity is adequate for patient use, higher levels of purity are desirable and preferable. As shown in FIGURE 12, the optimized purification scheme described above achieves a degree of purity that is greater than 99% and importantly reduces Chinese hamster ovary cell host proteins to less than 1 percent, as determined by the

5 Chinese Hamster Ovary Protein (CHOP) assay.

In a sixth aspect, the present invention features novel methods of treating diseases caused all or in part by a deficiency in  $\alpha$ -L-iduronidase. Recombinant  $\alpha$ -L-iduronidase provides enzyme replacement therapy in a canine model of MPS 1. This canine model is deficient in  $\alpha$ -L-iduronidase due to a genetic mutation and is similar to human MPS 1.

10 Purified, properly processed  $\alpha$ -L-iduronidase was administered intravenously to 11 dogs. In those dogs treated with weekly doses of 25,000 to 125,000 units per kg for 0.5, 3, 6 or 13 months, the enzyme was taken up in a variety of tissues and decreased the lysosomal storage in many tissues. The long term treatment of the disease was associated with clinical improvement in demeanor, joint stiffness, coat and growth. Higher doses of

15 therapy (125,000 units per kg per week) result in better efficacy, including normalization of urinary GAG excretion in addition to more rapid clinical improvement in demeanor, joint stiffness and coat.

Enzyme therapy at even small doses of 25,000 units (0.1 mg/kg/wk) resulted in significant enzyme distribution to some tissues and decreases in GAG storage. If

20 continued for over 1 year, some clinical effects were evident in terms of increased activity, size and overall appearance of health. The therapy at this dose did not improve other tissues that are important sites for disease in this entity such as cartilage and brain. Higher doses of 125,000 units (0.5 mg/kg) given 5 times over two weeks demonstrate that improved tissue penetration can be achieved, and a therapeutic effect at the tissue level

25 was accomplished in as little as 2 weeks. Studies at this increased dose have been completed in two dogs for 15 months. These MPS I dogs are showing significant clinical improvement and substantial decreases in urinary GAG excretion into the near normal range. Other than an immune reaction controlled by altered administration techniques, the enzyme therapy has not shown significant clinical or biochemical toxicity. Enzyme

30 therapy at this higher weekly dose is effective at improving some clinical features of MPS I and decreasing storage without significant toxicity.



In a seventh aspect, the present invention features novel pharmaceutical compositions comprising human  $\alpha$ -L-iduronidase useful for treating a deficiency in  $\alpha$ -L-iduronidase. The recombinant enzyme may be administered in a number of ways such as parenteral, topical, intranasal, inhalation or oral administration. Another aspect of the invention is to provide for the administration of the enzyme by formulating it with a pharmaceutically acceptable carrier, which may be solid, semi-solid, liquid, or an ingestible capsule. Examples of pharmaceutical compositions include tablets, drops such as nasal drops, compositions for topical application such as ointments, jellies, creams and suspensions, aerosols for inhalation, nasal spray, and liposomes. Usually the recombinant enzyme comprises between 0.01 and 99% or between 0.01 and 99% by weight of the composition, for example, between 0.01 and 20% for compositions intended for injection and between 0.1 and 50% for compositions intended for oral administration.

To produce pharmaceutical compositions in this form of dosage units for oral application containing a therapeutic enzyme, the enzyme may be mixed with a solid, pulverulent carrier, for example lactose, saccharose, sorbitol, mannitol, a starch such as potato starch, corn starch, amylopectin, laminaria powder or citrus pulp powder, a cellulose derivative or gelatin and also may include lubricants such as magnesium or calcium stearate or a Carbowax® or other polyethylene glycol waxes and compressed to form tablets or cores for dragees. If dragees are required, the cores may be coated for example with concentrated sugar solutions which may contain gum arabic, talc and/or titanium dioxide, or alternatively with a film forming agent dissolved in easily volatile organic solvents or mixtures of organic solvents. Dyestuffs can be added to these coatings, for example, to distinguish between different contents of active substance. For the composition of soft gelatin capsules consisting of gelatin and, for example, glycerol as a plasticizer, or similar closed capsules, the active substance may be admixed with a Carbowax® or a suitable oil, e.g., sesame oil, olive oil, or arachis oil. Hard gelatin capsules may contain granulates of the active substance with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives or gelatin, and may also include magnesium stearate or stearic acid as lubricants.

Therapeutic enzymes of the subject invention may also be administered parenterally such as by subcutaneous, intramuscular or intravenous injection or by

sustained release subcutaneous implant. In subcutaneous, intramuscular and intravenous injection, the therapeutic enzyme (the active ingredient) may be dissolved or dispersed in a liquid carrier vehicle. For parenteral administration, the active material may be suitably admixed with an acceptable vehicle, preferably of the vegetable oil variety such as peanut  
5 oil, cottonseed oil and the like. Other parenteral vehicles such as organic compositions using solketal, glycerol, formal, and aqueous parenteral formulations may also be used.

For parenteral application by injection, compositions may comprise an aqueous solution of a water soluble pharmaceutically acceptable salt of the active acids according to the invention, desirably in a concentration of 0.01-10%, and optionally also a  
10 stabilizing agent and/or buffer substances in aqueous solution. Dosage units of the solution may advantageously be enclosed in ampules.

When therapeutic enzymes are administered in the form of a subcutaneous implant, the compound is suspended or dissolved in a slowly dispersed material known to those skilled in the art, or administered in a device which slowly releases the active  
15 material through the use of a constant driving force such as an osmotic pump. In such cases, administration over an extended period of time is possible.

For topical application, the pharmaceutical compositions are suitably in the form of an ointment, gel, suspension, cream or the like. The amount of active substance may vary, for example, between 0.05- 20% by weight of the active substance. Such  
20 pharmaceutical compositions for topical application may be prepared in known manner by mixing the active substance with known carrier materials such as isopropanol, glycerol, paraffin, stearyl alcohol, polyethylene glycol, etc. The pharmaceutically acceptable carrier may also include a known chemical absorption promoter. Examples of absorption promoters are, *e.g.*, dimethylacetamide (U.S. Patent No. 3,472,931), trichloro ethanol or  
25 trifluoroethanol (U.S. Patent No. 3,891,757), certain alcohols and mixtures thereof (British Patent No. 1,001,949). A carrier material for topical application to unbroken skin is also described in the British patent specification No. 1,464,975, which discloses a carrier material consisting of a solvent comprising 40-70% (v/v) isopropanol and 0-60% (v/v) glycerol, the balance, if any, being an inert constituent of a diluent not exceeding  
30 40% of the total volume of solvent.

The dosage at which the therapeutic enzyme containing pharmaceutical compositions are administered may vary within a wide range and will depend on various

factors such as the severity of the disease, the age of the patient, etc., and may have to be individually adjusted. A possible range for the amount of therapeutic enzyme which may be administered per day is about 0.1 mg to about 2000 mg or about 1 mg to about 2000 mg.

5           The pharmaceutical compositions containing the therapeutic enzyme may suitably be formulated so that they provide doses within these ranges, either as single dosage units or as multiple dosage units. In addition to containing a therapeutic enzyme (or therapeutic enzymes), the subject formulations may contain one or more substrates or cofactors for the reaction catalyzed by the therapeutic enzyme in the compositions. Therapeutic  
10   enzymes containing compositions may also contain more than one therapeutic enzyme.

          The recombinant enzyme employed in the subject methods and compositions may also be administered by means of transforming patient cells with nucleic acids encoding the recombinant  $\alpha$ -L-iduronidase. The nucleic acid sequence so encoded may be incorporated into a vector for transformation into cells of the subject to be treated.  
15   Preferred embodiments of such vectors are described herein. The vector may be designed so as to integrate into the chromosomes of the subject, *e.g.*, retroviral vectors, or to replicate autonomously in the host cells. Vectors containing encoding  $\alpha$ -L-iduronidase nucleotide sequences may be designed so as to provide for continuous or regulated expression of the enzyme. Additionally, the genetic vector encoding the enzyme may be  
20   designed so as to stably integrate into the cell genome or to only be present transiently. The general methodology of conventional genetic therapy may be applied to polynucleotide sequences encoding  $\alpha$ -L-iduronidase. Conventional genetic therapy techniques have been extensively reviewed. (Friedman, *Science* 244:1275-1281 (1989); Ledley, J. *Inherit. Metab. Dis.* 13:587-616 (1990); Tososhev, *et al.*, *Curr Opinions*  
25   *Biotech.* 1:55-61 (1990)).

          A particularly preferred method of administering the recombinant enzyme is intravenously. A particularly preferred composition comprises recombinant  $\alpha$ -L-iduronidase, normal saline, phosphate buffer to maintain the pH at about 5.8 and human albumin. These ingredients may be provided in the following amounts:

30

$\alpha$ -L-iduronidase	0.05-0.2 mg/mL or 12,500-50,000 units per mL
Sodium chloride solution	150 mM in an IV bag, 50-250 cc total volume

Sodium phosphate buffer 10-50 mM, pH 5.8

Human albumin 1 mg/mL

Composition of Recombinant Human  $\alpha$ -L-Iduronidase (rhIDU,

5

Aldurazyme™) Drug Product

Name of Ingredient	Concentration	Composition per vial	Function
rhIDU	100 U/mL (Range: 80 – 150 U/mL)	3.07 mg	Active ingredient
NaCl	150 mM	46.5 mg	Tonicity Modifier
Sodium Phosphate monobasic	92 mM	67.3 mg	Buffer
Sodium Phosphate dibasic	8 mM	11.3 mg	Buffer
Polysorbate 80	10 g/mL	0.05 mg	Stabilizer

The proposed commercial formulation for Aldurazyme™ is 100 Units/mL (approximately 0.58 mg/mL) for recombinant human  $\alpha$ -L-Iduronidase (rhIDU), 100 mM sodium phosphate, 150 mM sodium chloride, and 10 M/mL polysorbate 80, pH of 5.8.

10 The Phase I study formula was identical to the Phase III study formula and proposed commercial formulation with the exception that polysorbate 80 was added as a stabilizer in the Phase III and commercial formula. This commercial formulation was also used in Good Laboratory Practice (GLP) toxicology studies.

Polysorbate 80, at a concentration of 10 M/mL was added to the formulation to  
 15 act as a stabilizer. The change was implemented when the rhIDU production process was scaled up and prompted by the observation of a fine precipitate in the vial drug product and coincided with the change from polypropylene vials to glass vials. Formulation studies have demonstrated that polysorbate-20 (10 M/mL) and polysorbate-80 (5  
 20 M/mL) both minimized the formation of precipitates in vial drug product even after forced agitation. The concentration of polysorbate-20 or polysorbate-80 needed to minimize the formation of precipitates was 5 M/mL for polysorbate-80 and 10 M/mL

for polysorbate-20. Preliminary data demonstrated that Aldurazyme™, when formulated with polysorbate 80 at 10 M/mL, retained activity when stored at 2-8°C. Polysorbate 80 was chosen over polysorbate 20 because it performed slightly better in preventing precipitate formation and it is more commonly used in marketed pharmaceutical product formulations. Polysorbate is known to be effective against agitation-induced aggregation of proteins, and a review of the literature regarding the use of polysorbate 80 in chronic intravenous therapies found the proposed level to be included in Aldurazyme™ (10 M/mL) to be well below that used in other pharmaceutical formulations (Bam, *et al.*, *J. Pharm. Sci.* 87(12):1554-9 (1998); Kreilgaard, *et al.*, *J. Pharm. Sci.* 87(12):1597-603 (1998)).

The safety and efficacy of the commercial formulation were assessed in Good Laboratory Practice (GLP) toxicology studies as well as Phase III study.

The invention having been described, the following examples are offered to illustrate the subject invention by way of illustration, not by way of limitation.

15

#### EXAMPLE 1

##### Producing Recombinant $\alpha$ -L-Iduronidase

Standard techniques such as those described by Sambrook, *et al* (*Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1987)) may be used to clone cDNA encoding human  $\alpha$ -L-iduronidase. The human  $\alpha$ -L-iduronidase cDNA previously cloned was subcloned into PRCCMV (InVitrogen) as a HindIII-XbaI fragment from a bluescript KS subclone. An intron cassette derived from the murine immunoglobulin Cot intron between exons 2 and 3 was constructed using PCR amplification of bases 788-1372 (Tucker, *et al.*, *Proc. Natl. Acad. Sci. USA* 78: 7684-7688 (1991) of clone pRIR14.5 (Kakkis, *et al.*, *Nucleic Acids Res.* 16:7796 (1988)). The cassette included 136 bp of the 3' end of exon 2 and 242 bp of the 5' end of exon 3, which would remain in the properly spliced cDNA. No ATG sequences are present in the coding region of the intron cassette. The intron cassette was cloned into the HindIII site 5' of the  $\alpha$ -L-iduronidase cDNA. The neo gene was deleted by digestion with XhoI followed by recircularizing the vector to make pCMVhldu.

30

One vial of the working cell bank is thawed and placed in three T225 flasks in DME/F12 or PF-CHO plus supplements, plus 5% FBS and 500  $\mu$ g/ml G418. After 2-5

days, the cells are passaged using trypsin-EDTA to a 1-liter spinner flask in the same medium for 2-5 days. The cells are then transferred to two 3-liter spinner flasks for 2-5 days, followed by four 8-liter spinner flasks for 2-5 days. The inoculum from the 8-liter spinner flasks is added to two 110-liter Applikon® stirred tank bioreactors with an 80-90  
5 liter working volume. Macroporous cellulose microcarriers are added at 2 grams per liter (160 grams), with PF-CHO or DME/F12 plus supplements, 5% FBS and 500 µg/ml of G418 at a final volume of 80-90 liters. The flask is stirred by an overhead drive with a marine impeller. The culture is monitored for agitation speed, temperature, DO and pH probes and controlled the Applikon® control system with a PC interface. The parameters  
10 are controlled at the set points or range, 35-37° C depending on culture conditions, 40% air saturation, and pH 6.95, using a heating blanket, oxygen sparger and base pump. The culture is incubated for 3-5 days at which time the culture is emerging from the log phase growth at  $1-3 \times 10^6$  cells per ml. Thereafter, perfusion is initiated at an increasing rate with PF-CHO medium (with custom modifications, JRH Biosciences). The first four days  
15 of collection (range of 3-5 days) are set aside as "washout." The collection thereafter is the beginning of the production run. Production continues with medium changes of as much as 2-3.5 culture volumes per day for 20-36 days. The culture may be extended for 40 days or longer. The culture is monitored for temperature, pH and DO on a continuous basis. The purification of the enzyme proceeds as described above. Collected production  
20 medium containing iduronidase is then acidified to pH 5.3, filtered through a 0.2-micron filter and purified using Blue-Sepharose chromatography. The purified enzyme from multiple rounds of Blue-Sepharose chromatography are then pooled and applied to a copper chelating column and eluted with glycerol in the buffer at a pH of 3.7. The enzyme is held at the acidic pH to inactivate potential viruses. The copper column eluate  
25 is then adjusted to pH 5.7 and 2 M NaCl and loaded on the phenyl Sepharose column. The enzyme is eluted at 0.7 M NaCl. The eluate is concentrated and diafiltered into a formulation buffer of 150 mM NaCl, 100 mM NaPO<sub>4</sub>, pH5.8. The enzyme is filtered through a 40 nM filter to remove potential viruses and the filtrate adjusted to 0.001% polysorbate 80. The formulated enzyme is sterilely bulk filled into sterile polyethylene  
30 containers. The bulk enzyme is then filtered and filled into 5 cc Type 1 glass vials appropriate for injectable pharmaceuticals, stoppered and capped.

### EXAMPLE 2

For bioreactors using single cell suspensions, the seed train is prepared as described above in EXAMPLE 1. Using a single cell suspension simplifies bioreactor preparation and inoculation. The bioreactor is inoculated with cells in DMEM/F12 medium (25% of reactor volume) and JRH 325 modified (25% of reactor volume). Medium equal to 50% of the working reactor volume is added over 48 hours. Perfusion (and harvest) is started when cell density reaches  $1.0 \times 10^6$  and the perfusion medium is the same as described above.

### EXAMPLE 3

Short-term intravenous administration of purified human recombinant  $\alpha$ -L-iduronidase to 9 MPS I dogs and 6 MPS I cats has shown significant uptake of an enzyme in a variety of tissues with an estimated 50% or more recovery in tissues 24 hours after a single dose. Although liver and spleen take up the largest amount of enzymes, and have the best pathologic improvement, improvements in pathology and glycosaminoglycan content has been observed in many, but not all tissues. In particular, the cartilage, brain and heart valve did not have significant improvement. Clinical improvement was observed in a single dog on long-term treatment for 13 months, but other studies have been limited to 6 months or less. All dogs, and most cats, that received recombinant human enzyme developed antibodies to the human product. The IgG antibodies are of the complement activating type (probable canine IgG equivalent). This phenomena is also observed in at least 13% of alglucerase-treated Gaucher patients. Proteinuria has been observed in one dog which may be related to immune complex disease. No other effects of the antibodies have been observed in the other treated animals. Specific toxicity was not observed and clinical laboratory studies (complete blood counts, electrolytes, BLJN/creatinine, liver enzymes, urinalysis) have been otherwise normal.

Enzyme therapy at even small doses of 25,000 units (0.1 mg/kg/wk) resulted in significant enzyme distribution to some tissues and decreases in GAG storage. If continued for over 1 year, significant clinical effects of the therapy were evident in terms of activity, size and overall appearance of health. The therapy at this dose did not improve other tissues that are important sites for disease in this entity such as cartilage and brain. Higher doses of 125,000 units (0.5 mg/kg) given 5 times over two weeks

demonstrate that improved tissue penetration can be achieved and a therapeutic effect at the tissue level was accomplished in as little as 2 weeks. Studies at this increased dose are ongoing in two dogs for six months to date. These MPS I dogs are showing significant clinical improvement and substantial decreases in urinary GAG excretion into the normal range. Other than an immune reaction controlled by altered administration techniques, the enzyme therapy has not shown significant clinical or biochemical toxicity. Enzyme therapy at this higher weekly dose is effective at improving some clinical features of MPS I and decreasing storage without significant toxicity.

The results of these various studies in MPS I dogs and one study in MPS I cats show that human recombinant  $\alpha$ -L-iduronidase is safe. Although these same results provide significant rationale that this recombinant enzyme should be effective in treating  $\alpha$ -L-iduronidase deficiency, they do not predict the clinical benefits or the potential immunological risks of enzyme therapy in humans.

#### 15 EXAMPLE 4

The human cDNA of  $\alpha$ -L-iduronidase predicts a protein of 653 amino acids and an expected molecular weight of 70,000 daltons after signal peptide cleavage. Amino acid sequencing reveals alanine 26 at the N-terminus giving an expected protein of 629 amino acids. Human recombinant  $\alpha$ -L-iduronidase has a Histidine at position 8 of the mature protein. The predicted protein sequence comprises six potential N-linked oligosaccharide modification sites. All of these sites are modified in the recombinant protein. The third and sixth sites have been demonstrated to contain one or more mannose 6-phosphate residues responsible for high affinity uptake into cells.

This peptide corresponds to Amino Acids 26-45 of Human Recombinant  $\alpha$ -L-iduronidase with an N-terminus alanine and the following sequence:

ala-glu-ala-pro-his-leu-val-his-val-asp-ala-ala-arg-ala-leu-trp-pro-leu-arg-arg  
(part of SEQ ID NO:2)

The recombinant enzyme has an apparent molecular weight of 82,000 daltons on SDS-PAGE due to carbohydrate modifications. Purified human recombinant  $\alpha$ -L-iduronidase has been sequenced by the UCLA Protein Sequencing facility. It is preferred to administer the recombinant enzyme intravenously. Human recombinant  $\alpha$ -L-iduronidase was supplied for the clinical trial in 10 mL polypropylene vials at a



concentration of 100,000-200,000 units per mL. The final dosage form of the enzyme used in the clinical trial includes human recombinant  $\alpha$ -L-iduronidase, normal saline, and 100 mM phosphate buffer at pH 5.8. These are prepared in a bag of normal saline. Polysorbate 80 at a final concentration of 0.001 % was added to the formulation to

5 stabilize the protein against shear, thereby avoiding precipitation in the final product vials.

#### Final Vial Formulation Currently in Use

<u>Component</u>	<u>Composition</u>
$\alpha$ -L-iduronidase	Target to 0.7 mg/mL or 100 (new) units per mL
Sodium chloride solution	150 mM
10 Sodium phosphate buffer	100 mM, pH 5.8
Polysorbate 80	0.001%

#### Final Dosage Form Used in the Treatment of Patients

<u>Component</u>	<u>Composition</u>
15 $\alpha$ -L-iduronidase product	5-12 fold dilution of vial concentration
Sodium chloride solution	50 mM Sodium phosphate buffer 100-250 cc IV bag
Human albumin	1 mg/ml

#### EXAMPLE 5

##### 20 **Phase I Study - Effects of Intravenous Administration of $\alpha$ -L-Iduronidase in Patients with Mucopolysaccharidosis I (52 weeks)**

Based on studies of cloning of cDNA encoding  $\alpha$ -L-iduronidase (Scott, *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 9695-99 (1991); Stoltzfus, *et al.*, *J. Biol. Chem.* 267: 6570-75 (1992)) and animal studies showing effects of  $\alpha$ -L-iduronidase to reduce

25 lysosomal storage in many tissues (Shull, *et al.*, *Proc. Natl. Acad. Sci. USA* 91: 12937-41 (1994); Kakkis, *et al.*, *Biochem. Mol. Med.* 58: 156-67 (1996)), a 52-week study was conducted to assess the safety and clinical efficacy of intravenous administration of highly purified  $\alpha$ -L-iduronidase in ten patients with mucopolysaccharidosis I (MPS I).

Recombinant human  $\alpha$ -L-iduronidase was produced and purified to greater than

30 97-99%. Patients demonstrated typical clinical manifestations of the disorder and diagnosis was confirmed by biochemical determination of  $\alpha$ -L-iduronidase deficiency in leukocytes.

Patients were given recombinant human  $\alpha$ -L-iduronidase (diluted in normal saline with 0.1% human serum albumin) intravenously at a dose of 125,000 units per kg (using original assay and unit definition); 3,000 units per kg were given over the first hour, and 61,000 units per kg in each of the following two hours. The dose of 125,000 units per kg is equivalent to 100 SI units per kg using the new assay. The infusions were prolonged up to 4-6 hours in patients who had hypersensitivity reactions.

At baseline and at 6, 12, 26 and 52 weeks depending on the evaluation, the patients underwent examinations including history, physical examinations by specialists, echocardiography, EKG, MRI, polysomnography (weeks 0 and 26), skeletal survey (weeks 0, 26, 52), range of motion measurements, corneal photographs, and skin biopsy (week 0) to set up fibroblast cultures for enzyme determination and genotyping. Range of motion measurements were performed with a goniometer and the maximum active (patient initiated) range was recorded for each motion. Shoulder flexion is movement of the elbow anteriorly from the side of the body and elbow and knee extension represent straightening of the joint. Degrees of restriction represent the difference between the normal maximum range of motion for age and the measured value. Polysomnography was performed according to American Thoracic Society guidelines and apneic events (cessation of oro-nasal airflow for 10 seconds or more), hypopneic events (decreased oro-nasal airflow of 50% or more with desaturation of 2% or more, or evidence of arousal), minutes below 89% oxygen saturation and total sleep time recorded among the standard measurements required. From these data an apnea/hypopnea index was calculated by dividing the total number of apneic and hypopneic events by the number of hours of sleep. Biochemical studies included measurement of enzyme activity in leukocytes and brushings of buccal mucosal, urinary glycosaminoglycan levels, and tests for serum antibodies to recombinant human  $\alpha$ -L-iduronidase (ELISA and Western blot). Organ volumes were determined by analysis of MRI digital image data using Advantage Windows workstation software from General Electric. The organ volume was measured in milliliters and was converted to weight assuming a density of 1 gram per ml. Urinary glycosaminoglycan excretion was assayed by an adaptation of a published method. Western blots and ELISA assays for antibodies to recombinant human  $\alpha$ -L-iduronidase were performed by standard methods. Uronic acids and N-sulfate of urinary

glycosaminoglycans were analyzed by the orcinol, carbazole and MBTH methods, and by electrophoretic separations.

All patients received weekly infusions of recombinant human  $\alpha$ -L-iduronidase administered for 52 weeks. The mean activity of  $\alpha$ -L-iduronidase in leukocytes was 0.04 units per mg before treatment and when measured on average 7 days after an infusion (i.e. immediately before the next infusion), 4.98 units per mg, or 15.0 percent of normal. Enzyme activity was not detectable in buccal brushings prior to treatment, but 7 days after infusions it reached a level of 1 percent of normal.

Liver volume decreased by 19 to 37 percent from baseline in 9 patients and 5 percent in one patient at 52 weeks; the mean decrease was 25.0 percent ( $n=10$ ,  $P<0.001$ ). By 26 weeks, liver size was normal for body weight and age in 8 patients (Figure 1). In 2 patients (patients 6 and 9) with the largest relative liver size at baseline, liver size was close to normal at 52 weeks (3.2 and 3.3 percent of body weight, respectively). Spleen size decreased in 8 patients by 13 to 42 percent from baseline (mean decrease of 20 percent in 10 patients,  $P<0.001$ ).

Urinary glycosaminoglycan excretion declined rapidly by 3 to 4 weeks and by 8-12 weeks had fallen by 60-80 percent of baseline. At 52 weeks, the mean reduction was 63 percent (range 53-74;  $p<0.001$ ). Eight of ten patients had a 75 percent or greater reduction of the baseline amount of urinary glycosaminoglycan in excess of the upper limit of normal for age. The results were confirmed by assay of uronic acids and N-sulfate (a test specific for heparan sulfate). Electrophoresis studies of urine detected a significant reduction in heparan sulfate and dermatan sulfate excretion but some excess dermatan sulfate excretion persisted in all patients.

The mean height increased 6.0 cm (5.2 percent) in the 6 prepubertal patients (Table 2) and their mean height growth velocity increased from 2.8 cm/yr to 5.2 cm/yr during treatment ( $P=0.011$ ). For all 10 patients, mean body weight increased 3.2 kg (8.8 percent) and the mean increase was 4.2 kg (17.1 percent) for the 6 prepubertal patients (Table 2). In these 6 patients, the mean pretreatment weight growth velocity increased from 1.7 kg per year to 3.8 kg per year during treatment ( $P=0.04$ ).

Shoulder flexion (moving the elbow anteriorly) increased in 6 of the 8 subjects evaluated at baseline with a mean improvement for the right and left shoulders of  $28^\circ$  and

26°, respectively ( $P < 0.002$ ; Figure 2). Elbow extension and knee extension increased by a mean of 7.0° ( $P < 0.03$ ) and 3.2° ( $P = 0.10$ ), respectively, in the 10 patients (Figure 2).

Analysis of the improvement in individual patients revealed that the most restricted joints had the greatest improvement. For example at baseline, patients 5, 9 and 10 could not flex their shoulders (move the elbow anteriorly) beyond 100°, which increased 21° to 51° after treatment. Similarly, patients 2 and 9 had a substantial increase in knee extension. The changes in range of motion were accompanied by patient-reported increases in physical activities such as being able to wash their hair, hold a hamburger normally, hang from monkey bars, and play sports better.

Seven patients had a decrease in apnea and hypopnea events from 155 to 60 per night upon treatment (a 61 percent decrease) with a change in mean apnea/hypopnea index (total number of events per hour) from 2.1 to 1.0. Three patients had clinically significant sleep apnea and all three improved during treatment. In patient 2, the apnea/hypopnea index decreased from 4.5 at baseline to 0.4 at 26 weeks and total time of oxygen desaturation decreased from 48 minutes to 1 minute per night. Patient 6 required nightly continuous positive airway pressure therapy before treatment due to severe desaturation (61 minutes below 89 percent saturation with continuous positive airway pressure in 368 minutes of sleep), but by 52 weeks, the patient tolerated the sleep study without CPAP and desaturated below 89 percent for only 8 minutes during 332 minutes of sleep. Patient 9 had an apnea hypopnea index of 9.5 which decreased to 4.0 by 26 weeks. Patient 8 worsened with an apnea hypopnea index of 0.1 increasing to 3.1 at 26 weeks and 9.3 at 52 weeks for unclear reasons. Eight of ten patients or their families reported improved breathing, and 5 of 7 noted quieter nighttime breathing, improved sleep quality and decreased daytime somnolence.

New York Heart Association functional classification was determined by serial patient interviews. All 10 patients reported improvement by one or two classes but there was no significant objective data from echocardiographic studies to verify direct cardiac benefit. The improved functional scores may reflect improvements in other aspects of MPS I disease rather than cardiac function. Comparing baseline to 52 weeks of treatment, echocardiography demonstrated decreased tricuspid regurgitation or pulmonic regurgitation in 4 patients but two patients (patients 2 and 7) had worsening mitral regurgitation. At baseline, patient 6 had atrial flutter and clinical signs of cardiac failure

including dyspnea at rest and peripheral edema. By 12 weeks, he had normal sinus rhythm with first degree block and his dyspnea at rest and pitting edema resolved.

All 10 patients reported a lack of endurance and limitations of daily activities before treatment but exercise tolerance was not formally tested. During treatment, all  
5 patients improved and by 26 weeks, many were able to walk more, run and play sports. Patients 3, 4 and 5 reported the resolution of severe incapacitating headaches after treatment for 6-12 weeks.

Several patients reported decreased photophobia or conjunctival irritation. Visual acuity improved in one patient (20/1000 to 20/200 in one eye) and modestly in 2 others.

10 The results of this study indicate that intravenous administration of the highly purified recombinant human  $\alpha$ -L-iduronidase of the present invention results in clinical and biochemical improvement in patients with Mucopolysaccharidosis I. The normalization of liver size and near normalization of urinary glycosaminoglycan excretion is consistent with data from studies in dogs with Mucopolysaccharidosis I, which  
15 demonstrated clearance of storage in the liver and decreased urinary glycosaminoglycan excretion in as little as 2 weeks.

Hypersensitivity reactions to the infusions of recombinant human  $\alpha$ -L-iduronidase were less severe than predicted from studies in dogs. Though important in some patients, recurrent urticaria was manageable with premedication and adjustments in infusion rate.  
20 Antibodies specific to  $\alpha$ -L-iduronidase were detected in 4 patients with usually subclinical complement activation, and both the antibodies and complement activation declined with time. Similar IgG-mediated immune responses have been previously noted in patients with Gaucher disease treat with glucocerebrosidase, although the events were more frequent in our patients. Mucopolysaccharidosis I patients with a null genotype may  
25 have a greater immune response than in these 10 patients, none of whom has a null.

Thus, recombinant human  $\alpha$ -L-iduronidase can reduce lysosomal storage and ameliorates some aspects of clinical disease of Mucopolysaccharidosis I.

#### EXAMPLE 6

30 Phase III Study - Effects of Intravenous Administration of  $\alpha$ -L-Iduronidase in Patients with Mucopolysaccharidosis I (26 weeks)

A multi-national, multi-center, double-blind, randomized, placebo-controlled study was conducted to further assess the safety and clinical efficacy of intravenous administration of highly purified  $\alpha$ -L-Iduronidase in 45 MPS I patients.

Recombinant human  $\alpha$ -L-Iduronidase was purified to greater than 99%. The  
5 patients were characterized by age of at least five years old, less than 10 percent of normal enzyme activity, a baseline forced vital capacity (FVC) reflecting pulmonary function of 80% or less of percent predicted normal, and a capability of standing for 6 minutes and walking at least 5 meters. Of the 45 patients, 22 patients were treated with highly purified  $\alpha$ -L-Iduronidase and the remaining 23 received a placebo. Patients were administered  
10 human  $\alpha$ -L-Iduronidase intravenously at a dose of 100 units per kilogram via a 4-hour intravenous infusion each week for 26 weeks.

#### *Efficacy Endpoints*

Patients were assessed by measuring primary efficacy endpoints, the change from baseline to week 26 in the % FVC and a six-minute walk distance using the Wilcoxon  
15 Rank Sum Test. Patients were further assessed by secondary efficacy endpoints including apnea/hypoxia index (sleep study), liver organ volume (hepatomegaly), disability score index (Child Health Assessment Questionnaire / Health Assessment Questionnaire, CHAQ/HAQ), and shoulder flexion reflecting joint range of motion. These endpoints were measured as a change in baseline to week 26 by the Analysis of Variance test.  
20 Patients were also assessed by measuring tertiary efficacy endpoints, including urinary glucosaminoglycan (GAG) levels, totally respiratory event index (sleep study), pain scale (CHAQ), shoulder extension, knee extension and flexion, quality of life (50-question Child Health Questionnaire Physical Functioning, CHQ PF 50; 87-question Child Health Questionnaire directed to the child with questions combined to create concepts, CHQ  
25 CF87; 36-question Short Form Health Status Survey, SF-36), growth in prepubertal only, visual acuity, echocardiogram, force expiratory volume (FEV<sub>1</sub>), and investigator global assessment. The investigator global assessment comprises a series of seven categories in which the investigator is providing an assessment as to how each patient is improving during the trial.

#### 30 *Safety Endpoints*

Safety was assessed by measurement of the frequency of adverse events, serious adverse events, and infusion-associated reactions, immunogenicity testing, and

measurement of other safety parameters by physical examinations, testing of vital signs, brain/cranio-cervical junction magnetic resonance imaging (MRI), and standard laboratory evaluations.

## Results

### 5 Efficacy Endpoints

With respect to primary efficacy endpoints, a statistically significant difference ( $p = 0.028$ ) was seen in the change in % predicted FVC (see Table I). A close to statistically significant difference ( $p = 0.066$ ) was noted in the change in 6-minute walk (Table II).

Although there was no significant overall difference observed in the sleep  
 10 apnea/hypopnea index, a reduction of events was observed in enzyme-treated patients with clinically significant disease ( $n = 6/9$ ,  $p = 0.011$ ). Consistent with the prior study, there was a significant reduction in liver volume ( $p = 0.001$ ) and hence improvement in occurrence of hepatomegaly. There were no significant differences in CHAQ/HAQ Disability Index or Joint Range of Motion, although there was a trend towards  
 15 improvement in more severe patients. There was a statistically significant rapid reduction in urinary GAG ( $p < 0.001$ ). Trends in favor of enzyme treatment were noted in measurements of right shoulder extension, left knee flexion, and LVDS (Left Ventricle Internal Dimension at End-Systole in cm) as measured by echocardiography.

Table I

20

Percent Predicted Change From Baseline

#### Intent To Treat Population

	Baseline	Week 26	Change	Difference from Placebo
	(% Predicted)	(% Predicted)		
$\alpha$ -L-Iduronidase (Aldurazyme™) $n = 22$	$48.4 \pm 14.85$	$50.2 \pm 17.10$	$1.8 \pm 7.70$	4.5 $p = 0.028$
Placebo $n = 23$	$54.2 \pm 16.00$	$51.5 \pm 13.13$	$-2.7 \pm 7.12$	

Table II

Six-Minute Walk Change from Baseline

## Intent To Treat Population

	Baseline (m)	Week 26 (m)	Change	Difference from Placebo
$\alpha$ -L-Iduronidase (Aldurazyme™) n = 22	319.0 $\pm$ 131.41	338.8 $\pm$ 127.06	19.7 $\pm$ 68.56	38.1 p = 0.066
Placebo n = 23	366.7 $\pm$ 113.68	348.3 $\pm$ 128.81	-18.3 $\pm$ 67.49	

5

*Comparison with Phase I Study*

The results from measurement of secondary and tertiary endpoints were consistent with that of the Phase I study. For example, in both studies there was a significant reduction in liver volume (p = 0.001). Liver volume recovered to normal in almost 60% of enzyme-treated patients in the Phase III study at the end of 26 weeks. Similarly, in the Phase I study, liver size was normal for body weight and age in eight of ten patients by 26 weeks. In both studies, there was a reduction in sleep apnea/hypopnea events. As described above, in the Phase III study, a reduction in events (p=0.011) was observed in six of nine enzyme-treated patients with clinically significant disease. Similarly, seven of ten patients in the Phase I study showed a decrease in apnea and hypopnea events from 155 to 60 per night upon treatment with a reduction in the mean apnea/hypopnea index. There was also an improvement in the joint range of motion of more severe patients treated with the enzyme. Urinary GAG excretion rapidly declined in enzyme-treated patients in both studies. In the Phase III study, there was a statistically significant rapid reduction in urinary GAG levels (p < 0.001). Similarly, in the Phase I study, urinary GAG excretion declined rapidly by three to four weeks and by eight to twelve weeks had fallen by 60 – 80% of baseline. Thus, there appeared to a strong correlations in the secondary and tertiary efficacy endpoints of Phase I and III studies.

The results show that  $\alpha$ -L-Iduronidase appears to be safe and well-tolerated. The types of adverse events were similar between days of infusion and non-infusion days. The



frequency of infusion – associated reactions was similar between placebo and enzyme-treated groups. With respect to immunogenicity testing of IgG, all 22 patients in the enzyme-treated group seroconverted with a mean time to seroconversion of 41 days. Seroconversion did not result in increased infusion-associated reactions or other adverse events. Among three patients tested for IgE, including one patient from the placebo group and two enzyme-treated patients, all IgE tests were negative. There were no clinically significant changes in observations from physical examination, vital, and brain / cranio – cervical junction MRI from baseline to week 26. Standard laboratory evaluations showed: (1) no significant laboratory changes indicating a negative treatment effect; (2) a significant increase in platelet counts in enzyme –treated patients; and (3) improvement in liver enzyme abnormalities in enzyme-treated patients.

### *Summary*

In the Phase I studies i) all patients developed antibodies to the treatment with all 10 to contaminating proteins and 4 to IDU itself; ii) 5 patients (50%) had clinical manifestations of an allergic response of which the most common urticaria (hives); and iii) several of these reactions were classified as serious adverse events (SAEs) (meaning they required medical intervention) related to treatment with  $\alpha$ -L-Iduronidase .

In the Phase III study, i) all patients developed antibodies to the treatment but it is not yet known whether these were to CP or IDU itself; ii) clinical manifestations of an allergic response were mild in all patients and were comparable between the placebo and  $\alpha$ -L-Iduronidase treated groups; iii) there were no SAEs considered related to treatment with  $\alpha$ -L-Iduronidase; and iv) there was no urticaria reported.

In summary, the efficacy data gathered in the MPS I dog studies and the two human clinical trials tells a consistent story of improvement in disease symptoms. The safety profile of the product improved significantly in the Phase III versus the Phase I. This corroborates the theory that the material of increased purity used in the Phase III trial is an improvement over the material used in the Phase I trial.

The invention, and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that

5 modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

WHAT IS CLAIMED IS:

1. A formulation of a pharmaceutical composition comprising a human recombinant  $\alpha$ -L-iduronidase or biologically active fragments or mutein thereof with a purity of greater than 99%, or in combination with a pharmaceutically suitable carrier.  
5
2. The formulation of claim 1, wherein said recombinant  $\alpha$ -L-iduronidase or biologically active fragments or mutein thereof with a specific activity of greater than about 240,000 units per milligram protein.
- 10 3. The pharmaceutical composition of claim 1 further comprising a sodium chloride solution, a buffer and polysorbate 80.
4. The pharmaceutical composition of claim 1 wherein said human recombinant  $\alpha$ -L-iduronidase or mutein thereof is present at a concentration range of  
15 about 80 to 150 units per mL.
5. The pharmaceutical composition of claim 1 wherein said human recombinant  $\alpha$ -L-iduronidase or mutein thereof is present at a concentration of about 100 units per mL.  
20
6. The pharmaceutical composition of claim 3 wherein said sodium chloride solution is at a concentration of about 150 mM.
7. The pharmaceutical composition of claim 3 wherein said buffer is a  
25 sodium phosphate monobasic buffer at a concentration of about 92 mM.
8. The pharmaceutical composition of claim 3 wherein said buffer is a sodium phosphate dibasic buffer at a concentration of about 8 mM.
- 30 9. The pharmaceutical composition of claim 3 after dilution into the dosage form wherein said human albumin is present at a concentration of at least about 1 mg/mL.

10. The pharmaceutical composition of Claim 9 wherein human albumin is used to prevent or reduce acute allergic or complement mediated reactions in said human subject.

5 11. The pharmaceutical composition of claim 3 wherein the pH of said solution is maintained at about 5.8.

12. The pharmaceutical composition of claim 3 wherein said polysorbate 80 is maintained at 10 M/mL.

10

13. The pharmaceutical composition of claim 12 wherein said polysorbate is required to stabilize the protein in the final product.

14. A method of treating diseases caused all or in part by a deficiency in  $\alpha$ -L-iduronidase, comprising the steps of:

15

(a) administering said formulation of Claim 3 to a human subject in need thereof;

(b) optimizing said treatment by assessment of primary efficacy endpoints;

20

(c) optimizing said treatment by assessment of secondary efficacy endpoints;

(d) optimizing said treatment by assessment of tertiary efficacy endpoints; and

(e) optimizing treatment by assessment of safety endpoints.

25

15. The method of Claim 14, wherein said primary efficacy endpoints are selected from the group consisting of percent predicted forced vital capacity and six-minute walk distance.

30 16. The method of Claim 14, wherein said secondary efficacy endpoints are selected from the group consisting of apnea/hypopnea index, liver organ volume, disability score index, and joint range of motion.

17. The method of Claim 14, wherein said tertiary efficacy endpoints are selected from the group consisting of urinary glucosaminoglycan levels, total respiratory event index, pain, joint range of motion, quality of life, growth in prepubertal patients, visual acuity, echocardiogram, and forced expiratory volume.

5

18. The method of Claim 14 wherein the disease is mucopolysaccharidosis.

19. The method of Claim 14 wherein the disease is MPS I.

10

20. The method of Claim 14 wherein the disease is selected from the group consisting of: Hurler's disease, Scheie syndrome and Hurler-Scheie syndrome.

21. The method of Claim 14 wherein said subject suffering from the disease demonstrates about 1% or less of a normal  $\alpha$ -L-iduronidase activity.

15

22. The method of Claim 14 wherein a dose of at least about 100 units per kilogram said human recombinant  $\alpha$ -L-iduronidase is administered weekly to a patient suffering from a deficiency thereof.

20

23. The method of Claim 22, wherein said dose is administered over a four-hour infusion.

24. The method of Claim 14 wherein said administering is the slow infusion of at least 0.5 mg/kg of said formulation for about an hour, followed by a rapid two-hour infusion rate.

25

25. The method of Claim 24 wherein said infusion is used to minimize complement mediation clinical allergic reactions.

30

26. The method of Claim 14 wherein said treatment with human recombinant  $\alpha$ -L-iduronidase reduces lysosomal storage.

27. The method of Claim 14 wherein said treatment causes improvement in said endpoints of said human subjects.

28. The method of Claim 14 wherein said treatment results in improvement in  
5 percent forced vital capacity, improvement in six-minute walk, normalization of liver  
volume and urinary glycosaminoglycan excretion, reduction in spleen size and  
apnea/hypopnea events, increase in height and growth velocity in prepubertal patients,  
improvement in shoulder flexion and elbow and knee extension, improvement in  
symptoms related to cardiac function, and improvement in endurance and limitations of  
10 daily activities.

equence Range: 1 to 6200

```

      10      20      30      40      50      60      70
      *      *      *      *      *      *      *
GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG CCGCATAGTT

      80      90     100     110     120     130     140
      *      *      *      *      *      *      *
AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA

     150     160     170     180     190     200     210
      *      *      *      *      *      *      *
ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTCGG CTGCTTCGCG

     220     230     240     250     260     270     280
      *      *      *      *      *      *      *
ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC TAGTTATTA TAGTAATCAA TTACGGGGTC

     290     300     310     320     330     340     350
      *      *      *      *      *      *      *
ATTAGTTCAT AGCCCATATA TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGCCCCGCC TGGCTGACCG

     360     370     380     390     400     410     420
      *      *      *      *      *      *      *
CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC

     430     440     450     460     470     480     490
      *      *      *      *      *      *      *
ATTGACGTCA ATGGGTGGAC TATTTACGGT AAATGCCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC

     500     510     520     530     540     550     560
      *      *      *      *      *      *      *
AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCGTGGCATT ATGCCCAGTA CATGACCTTA

     570     580     590     600     610     620     630
      *      *      *      *      *      *      *
TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC CATGGTGATG CCGTTTTCGG

     640     650     660     670     680     690     700
      *      *      *      *      *      *      *
AGTACATCAA TGGGCGTGGG TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA

     710     720     730     740     750     760     770
      *      *      *      *      *      *      *
TGGGAGTTTG TTTTGGCACC AAAATCAACG GGAATTTCCA AAATGTCGTA ACAAATCCGC CCCATTGACG

     780     790     800     810     820     830     840
      *      *      *      *      *      *      *
CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA

     850     860     870     880     890     900     910
      *      *      *      *      *      *      *
CTGCTTAACT GGCTTATCGA AATTAAATAG ACTCACTATA GGGAGACCCA AGCTTCGCAG AATTCCTGCG

     920     930     940     950     960     970     980
      *      *      *      *      *      *      *
GCTGCTACAG TGTGTCCAGC GTCCTGCCTG GCTGTGCTGA GUGCTGGAAC AGTGGCGCAT CATTCAGTGT

     990    1000    1010    1020    1030    1040    1050
      *      *      *      *      *      *      *
CACAGTTACC CATCTGAGT CTGGCACCTT AACTGGCACA ATTGCCAAAG TCACAGGTGA GCTCAGATGC

```

FIGURE 1

PDB/US019/478BB

1060      1070      1080      1090  
ATACCAGGAC ATTGTATGAC GTTCCCTGCT CACATGCCTG CTTTCTTCCT ATAATACAGA TGCTCAACTA

1130      1140      1150      1160      1170      1180      1190  
ACTGCTCATG TCCTTATATC ACAGAGGGAA ATTGGAGCTA TCTGAGGAAC TGCCCAGAAG GGAAGGGCAG

1200      1210      1220      1230      1240      1250      1260  
AGGGGTCTTG CTCTCCTTGT CTGAGCCATA ACTCTTCTTT CTACCTTCCA GTGAACACCT TCCCACCCCA

1270      1280      1290      1300      1310      1320      1330  
GGTCCACCTG CTACCGCCGC CGTCGGAGGA GCTGGCCCTG AATGAGCTCT TGTCCTTGAC ATGCCTGGTG

1340      1350      1360      1370      1380      1390      1400  
CGAGCTTTCA ACCCTAAAGA AGTGCTGGTG CGATGGCTGC ATGGAAATGA GGAGCTGTCC CCAGAAAGCT

1410      1420      1430      1440      1450      1460      1470  
ACCTAGTGTG TGAGCCCCTA AAGGAGCCAG GCGAGGGAGC CACCACCTAC CTGGTGACAA GEGTGTGGCG

1480      1490      1500      1510      1520      1530      1540  
TGTATCAGCT GAAAGCTTGA TATCGAATTC CGGAGGCCGA ACCGGCAGTG CAGCCCGAAG CCCCGCAGTC

1550      1560      1570      1580      1590  
CCCCGAGCACG CGTGGGCC ATG CGT CCC CTG CGC CCC CGC GCC GCG CTG CTG GCG CTC CTG  
Met Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_>

1600      1610      1620      1630      1640      1650  
GCC TCG CTC CTG GCC GCG CCC CCG GTG GCC CCG GCC GAG GCC CCG CAC CTG GTG CAT  
Ala Ser Leu Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val His>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_>

1660      1670      1680      1690      1700      1710  
GTG GAC GCG GCC CGC GCG CTG TGG CCC CTG CGG CGC TTC TGG AGG AGC ACA GGC TTC  
Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg Ser Thr Gly Phe>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_>

1720      1730      1740      1750      1760      1770  
TGC CCC CCG CTG CCA CAC AGC CAG GCT GAC CAG TAC GTC CTC AGC TGG GAC CAG CAG  
Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr Val Leu Ser Trp Asp Gln Gln>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_>

1780      1790      1800      1810      1820  
CTC AAC CTC GCC TAT GTG GGC GCC GTC CCT CAC CGC GGC ATC AAG CAG GTC CGG ACC  
Leu Asn Leu Ala Tyr Val Gly Ala Val Pro His Arg Gly Ile Lys Gln Val Arg Thr>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_>

1830      1840      1850      1860      1870      1880  
CAC TGG CTG CTG GAG CTT GTC ACC ACC AGG GGG TCC ACT GGA CGG GGC CTG AGC TAC  
His Trp Leu Leu Glu Leu Val Thr Thr Arg Gly Ser Thr Gly Arg Gly Leu Ser Tyr>

**FIGURE 1A**



a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_

1890                  1900                  1910                  1920                  1930                  1940  
\* \* \* \* \*  
AAC TTC ACC CAC CTG GAC GGG TAC CTG GAC CTT CTC AGG GAG AAC CAG CTC CTC CCA  
Asn Phe Thr His Leu Asp Gly Tyr Leu Asp Leu Leu Arg Glu Asn Gln Leu Leu Pro>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

1950                  1960                  1970                  1980                  1990  
\* \* \* \* \*  
GGG TTT GAG CTG ATG GGC AGC GCC TCG GGC CAC TTC ACT GAC TTT GAG GAC AAG CAG  
Gly Phe Glu Leu Met Gly Ser Ala Ser Gly His Phe Thr Asp Phe Glu Asp Lys Gln>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2000                  2010                  2020                  2030                  2040                  2050  
\* \* \* \* \*  
CAG GTG TTT GAG TGG AAG GAC TTG GTC TCC AGC CTG GCC AGG AGA TAC ATC GGT AGG  
Gln Val Phe Glu Trp Lys Asp Leu Val Ser Ser Leu Ala Arg Arg Tyr Ile Gly Arg>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2060                  2070                  2080                  2090                  2100                  2110  
\* \* \* \* \*  
TAC GGA CTG GCG CAT GTT TCC AAG TGG AAC TTC GAG ACG TGG AAT GAG CCA GAC CAC  
Tyr Gly Leu Ala His Val Ser Lys Trp Asn Phe Glu Thr Trp Asn Glu Pro Asp His>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2120                  2130                  2140                  2150                  2160  
\* \* \* \* \*  
CAC GAC TTT GAC AAC GTC TCC ATG ACC ATG CAA GGC TTC CTG AAC TAC TAC GAT GCC  
His Asp Phe Asp Asn Val Ser Met Thr Met Gln Gly Phe Leu Asn Tyr Tyr Asp Ala>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2170                  2180                  2190                  2200                  2210                  2220  
\* \* \* \* \*  
TGC TCG GAG GGT CTG CGC GCC GCC AGC CCC GCC CTG CGG CTG GGA GGC CCC GGC GAC  
Cys Ser Glu Gly Leu Arg Ala Ala Ser Pro Ala Leu Arg Leu Gly Gly Pro Gly Asp>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2230                  2240                  2250                  2260                  2270                  2280  
\* \* \* \* \*  
TCC TTC CAC ACC CCA CCG CGA TCC CCG CTG AGC TGG GGC CTC CTG CGC CAC TGC CAC  
Ser Phe His Thr Pro Pro Arg Ser Pro Leu Ser Trp Gly Leu Leu Arg His Cys His>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2290                  2300                  2310                  2320                  2330                  2340  
\* \* \* \* \*  
GAC GGT ACC AAC TTC TTC ACT GGG GAG GCG GGC GTG CGG CTG GAC TAC ATC TCC CTC  
Asp Gly Thr Asn Phe Phe Thr Gly Glu Ala Gly Val Arg Leu Asp Tyr Ile Ser Leu>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2350                  2360                  2370                  2380                  2390  
\* \* \* \* \*  
CAC AGG AAG GGT GCG CGC AGC TCC ATC TCC ATC CTG GAG CAG GAG AAG GTC GTC GCG  
His Arg Lys Gly Ala Arg Ser Ser Ile Ser Ile Leu Glu Gln Glu Lys Val Val Ala>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

2400                  2410                  2420                  2430                  2440                  2450  
\* \* \* \* \*  
CAG CAG ATC CGG CAG CTC TTC CCC AAG TTC GCG GAC ACC CCC ATT TAC AAC GAC GAG  
Gln Gln Ile Arg Gln Leu Phe Pro Lys Phe Ala Asp Thr Pro Ile Tyr Asn Asp Glu>  
a \_ a \_ a \_ a \_ a \_ a \_ ORF RF[1] a \_ a \_ a \_ a \_ a \_ a \_ a \_>

**FIGURE 1B**

2490 PCT / 0001 / 47835

2460            2470            2480            \*            \*

\*            \*            \*            \*            \*

GCG GAC CCG CTG GTG GGC TGG TCC CTG CCA CAG CCG TGG AGG GCG GAC GTG ACC TAC  
Ala Asp Pro Leu Val Gly Trp Ser Leu Pro Gln Pro Trp Arg Ala Asp Val Thr Tyr>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2520            2530            2540            2550            2560

\*            \*            \*            \*            \*

GCG GCC ATG GTG GTG AAG GTC ATC GCG CAG CAT CAG AAC CTG CTA CTG GCC AAC ACC  
Ala Ala Met Val Val Lys Val Ile Ala Gln His Gln Asn Leu Leu Leu Ala Asn Thr>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2570            2580            2590            2600            2610            2620

\*            \*            \*            \*            \*            \*

ACC TCC GCC TTC CCC TAC GCG CTC CTG AGC AAC GAC AAT GCC TTC CTG AGC TAC CAC  
Thr Ser Ala Phe Pro Tyr Ala Leu Leu Ser Asn Asp Asn Ala Phe Leu Ser Tyr His>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2630            2640            2650            2660            2670            2680

\*            \*            \*            \*            \*            \*

CCG CAC CCC TTC GCG CAG CGC ACG CTC ACC GCG CGC TTC CAG GTC AAC AAC ACC GCG  
Pro His Pro Phe Ala Gln Arg Thr Leu Thr Ala Arg Phe Gln Val Asn Asn Thr Arg>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2690            2700            2710            2720            2730

\*            \*            \*            \*            \*

CCG CCG CAC GTG CAG CTG TTG CGC AAG CCG GTG CTC ACG GCC ATG GGG CTG CTG GCG  
Pro Pro His Val Gln Leu Leu Arg Lys Pro Val Leu Thr Ala Met Gly Leu Leu Ala>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2740            2750            2760            2770            2780            2790

\*            \*            \*            \*            \*            \*

CTG CTG GAT GAG GAG CAG CTC TGG GCC GAA GTG TCG CAG GCC GGG ACC GTC CTG GAC  
Leu Leu Asp Glu Glu Gln Leu Trp Ala Glu Val Ser Gln Ala Gly Thr Val Leu Asp>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2800            2810            2820            2830            2840            2850

\*            \*            \*            \*            \*            \*

AGC AAC CAC ACG GTG GGC GTC CTG GCC AGC GCC CAC CGC CCC CAG GGC CCG GCC GAC  
Ser Asn His Thr Val Gly Val Leu Ala Ser Ala His Arg Pro Gln Gly Pro Ala Asp>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2860            2870            2880            2890            2900            2910

\*            \*            \*            \*            \*            \*

GCC TGG CGC GCC GCG GTG CTG ATC TAC GCG AGC GAC GAC ACC CGC GCC CAC CCC AAC  
Ala Trp Arg Ala Ala Val Leu Ile Tyr Ala Ser Asp Asp Thr Arg Ala His Pro Asn>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2920            2930            2940            2950            2960

\*            \*            \*            \*            \*

GCG AGC GTC GCG GTG ACC CTG CCG CTG CGC GGG GTG CCC CCC GGC CCG GGC CTG GTC  
Arg Ser Val Ala Val Thr Leu Arg Leu Arg Gly Val Pro Pro Gly Pro Gly Leu Val>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

2970            2980            2990            3000            3010            3020

\*            \*            \*            \*            \*            \*

TAC GTC ACG CGC TAC CTG GAC AAC GGG CTC TGC AGC CCC GAC GGC GAG TGG CCG CGC  
Tyr Val Thr Arg Tyr Leu Asp Asn Gly Leu Cys Ser Pro Asp Gly Glu Trp Arg Arg>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3030            3040            3050            3060            3070            3080

\*            \*            \*            \*            \*            \*

**FIGURE 1C**

CTG GCG CGC CCC GTC TTC CCC ACG GCA GAG CAG TTT GGT CCG TAG TGC GGG GCG GAG  
Leu Gly Arg Pro Val Phe Pro Thr Ala Glu Gln Phe Arg Arg Met Arg Ala Ala Glu>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3090 3100 3110 3120 3130  
\* \* \* \* \*  
GAC CCG GTG GCC GCG GCG CCC CGC CCC TTA CCC GCC GGC GGC CGC CTG ACC CTG CGC  
Asp Pro Val Ala Ala Ala Pro Arg Pro Leu Pro Ala Gly Gly Arg Leu Thr Leu Arg>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3140 3150 3160 3170 3180 3190  
\* \* \* \* \*  
CCC GCG CTG CGG CTG CCG TCG CTT TTG CTG GTG CAC GTG TGT GCG CGC CCC GAG AAG  
Pro Ala Leu Arg Leu Pro Ser Leu Leu Leu Val His Val Cys Ala Arg Pro Glu Lys>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3200 3210 3220 3230 3240 3250  
\* \* \* \* \*  
CCG CCC GGG CAG GTC ACG CGG CTC CGC GCC CTG CCC CTG ACC CAA GGG CAG CTG GTT  
Pro Pro Gly Gln Val Thr Arg Leu Arg Ala Leu Pro Leu Thr Gln Gly Gln Leu Val>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3260 3270 3280 3290 3300  
\* \* \* \* \*  
CTG GTC TGG TCG GAT GAA CAC GTG GGC TCC AAG TGC CTG TGG ACA TAC GAG ATC CAG  
Leu Val Trp Ser Asp Glu His Val Gly Ser Lys Cys Leu Trp Thr Tyr Glu Ile Gln>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3310 3320 3330 3340 3350 3360  
\* \* \* \* \*  
TTC TCT CAG GAC GGT AAG GCG TAC ACC CCG GTC AGC AGG AAG CCA TCG ACC TTC AAC  
Phe Ser Gln Asp Gly Lys Ala Tyr Thr Pro Val Ser Arg Lys Pro Ser Thr Phe Asn>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3370 3380 3390 3400 3410 3420  
\* \* \* \* \*  
CTC TTT GTG TTC AGC CCA GAC ACA GGT GCT GTC TCT GGC TCC TAC CGA GTT CGA GCC  
Leu Phe Val Phe Ser Pro Asp Thr Gly Ala Val Ser Gly Ser Tyr Arg Val Arg Ala>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3430 3440 3450 3460 3470 3480  
\* \* \* \* \*  
CTG GAC TAC TGG GCC CGA CCA GGC CCC TTC TCG GAC CCT GTG CCG TAC CTG GAG GTC  
Leu Asp Tyr Trp Ala Arg Pro Gly Pro Phe Ser Asp Pro Val Pro Tyr Leu Glu Val>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3490 3500 3510 3520 3530 3540  
\* \* \* \* \*  
CCT GTG CCA AGA GGG CCC CCA TCC CCG GGC AAT CCA TGAG CCTGTGCTGA GCCCCAGTGG  
Pro Val Pro Arg Gly Pro Pro Ser Pro Gly Asn Pro>  
\_ \_ \_ \_ \_ ORF RF[1] \_ \_ \_ \_ \_

3550 3560 3570 3580 3590 3600 3610  
\* \* \* \* \*  
GTTGCACCTC CACCGGCAGT CAGCGAGCTG GGGCTGCACT GTGCCCATGC TGCCCTCCCA TCACCCCTTT  
3620 3630 3640 3650 3660 3670 3680  
\* \* \* \* \*  
TGCAATATAT TTTTATATTT TAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA  
3690 3700 3710 3720 3730 3740 3750  
\* \* \* \* \*

**FIGURE 1D**

AAAAAAAAAA AAAAAAAAAAG AATTCCTGCA GCCCGGGGGA TCCACTAGTT CTTGAGGCC CTTTCTAGC  
 3760 3770 3780 3790 3800 3810 3820  
 \* \* \* \* \*  
 CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG CCCCTCCCCC GTGCCTTCCT  
 3830 3840 3850 3860 3870 3880 3890  
 \* \* \* \* \*  
 TGACCCCTGGA AGGTGCCACT CCCACTGTCC TTTCCTAATA AAATGAGGAA ATTGCATCGC ATTGTCTGAG  
 3900 3910 3920 3930 3940 3950 3960  
 \* \* \* \* \*  
 TAGGTGTCAT TCTATTCTGG GGGGTGGGGT GGGGCAGGAC AGCAAGGGGG AGGATTGGGA AGACAATAGC  
 3970 3980 3990 4000 4010 4020 4030  
 \* \* \* \* \*  
 AGGCATGCTG GGGATGCGGT GGGCTCTATG GCTTCTGAGG CGGAAAGAAC CAGCTGGGGC TCGAGAGCTT  
 4040 4050 4060 4070 4080 4090 4100  
 \* \* \* \* \*  
 GCGCTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATCCACA CAACATACGA  
 4110 4120 4130 4140 4150 4160 4170  
 \* \* \* \* \*  
 GCCGGAAGCA TAAAGTGTA AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT  
 4180 4190 4200 4210 4220 4230 4240  
 \* \* \* \* \*  
 CACTGCCCCG TTTCAGTCG GGAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCAAC GCGCGGGGAG  
 4250 4260 4270 4280 4290 4300 4310  
 \* \* \* \* \*  
 AGGCGGTTTG CGTATTGGGC GCTCTTCGCG TTCCTCGCTC ACTGACTCGC TCGGTCGGT CGTTCGGCTG  
 4320 4330 4340 4350 4360 4370 4380  
 \* \* \* \* \*  
 CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA  
 4390 4400 4410 4420 4430 4440 4450  
 \* \* \* \* \*  
 AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTCCTA  
 4460 4470 4480 4490 4500 4510 4520  
 \* \* \* \* \*  
 TAGGCTCCGC CCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA  
 4530 4540 4550 4560 4570 4580 4590  
 \* \* \* \* \*  
 CTATAAAGAT ACCAGGCGTT TCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA  
 4600 4610 4620 4630 4640 4650 4660  
 \* \* \* \* \*  
 CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTCTCAA TGCTCACGCT GTAGGTATCT  
 4670 4680 4690 4700 4710 4720 4730  
 \* \* \* \* \*  
 CAGTTCGGTG TAGGTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC  
 4740 4750 4760 4770 4780 4790 4800  
 \* \* \* \* \*  
 GCCTTATCCG GTAACATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA

FIGURE 1E

PCT/US01/47835

4810 4820 4830 4840 4850 4860 4870 4880  
 \* \* \* \* \*  
 CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA

4880 4890 4900 4910 4920 4930 4940  
 \* \* \* \* \*  
 CGGCTACACT AGAAGGACAG TATTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT

4950 4960 4970 4980 4990 5000 5010  
 \* \* \* \* \*  
 GGTAGCTCTT GATCCGGCAA ACAACCACC GCTGGTAGCG GTGGTTTTTT TGTTCGCAAG CAGCAGATTA

5020 5030 5040 5050 5060 5070 5080  
 \* \* \* \* \*  
 CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGAACGA

5090 5100 5110 5120 5130 5140 5150  
 \* \* \* \* \*  
 AAACCTCACGT TAAGGGATT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTAAATTAA

5160 5170 5180 5190 5200 5210 5220  
 \* \* \* \* \*  
 AAATGAAGTT TTAATCAAT CTAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA

5230 5240 5250 5260 5270 5280 5290  
 \* \* \* \* \*  
 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC TGACTCCCG TCCTGTAGAT

5300 5310 5320 5330 5340 5350 5360  
 \* \* \* \* \*  
 AACTACGATA CGGAGGGCT TACCATCTGG CCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG

5370 5380 5390 5400 5410 5420 5430  
 \* \* \* \* \*  
 GCTCCAGATT TATCAGCAAT AAACAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT

5440 5450 5460 5470 5480 5490 5500  
 \* \* \* \* \*  
 CGGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTCCG

5510 5520 5530 5540 5550 5560 5570  
 \* \* \* \* \*  
 CAACGTTGTT GCCATGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTG GTATGGCTTC ATTCAGCTCC

5580 5590 5600 5610 5620 5630 5640  
 \* \* \* \* \*  
 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAA AGCGGTTAGC TCCTTCGGTC

5650 5660 5670 5680 5690 5700 5710  
 \* \* \* \* \*  
 CTCCGATCGT TGTGAGAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC

5720 5730 5740 5750 5760 5770 5780  
 \* \* \* \* \*  
 TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA

5790 5800 5810 5820 5830 5840 5850  
 \* \* \* \* \*  
 TAGTGTATGC GGCACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGGCCA CATAGCAGAA

5860 5870 5880 5890 5900 5910 5920  
 \* \* \* \* \*


FIGURE 1F

CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG AAATCTCTCA AGCATCTTAC GCTCTCTTAA  
5930 5940 5950 5960 5970 5980 5990  
\* \* \* \* \*  
ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT  
6000 6010 6020 6030 6040 6050 6060  
\* \* \* \* \*  
GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAGG GAATAAGGGC GACACGGAAA TGTGAATAC  
6070 6080 6090 6100 6110 6120 6130  
\* \* \* \* \*  
TCATACTCTT CCTTTTTCAT TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT  
6140 6150 6160 6170 6180 6190 6200  
\* \* \* \* \*  
TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC


FIGURE 1G

**FIGURE 2. SDS-POLYACRYLAMIDE GELS DEMONSTRATING IMPROVEMENTS IN PURITY**

Gel using the Kakkis et al 1994, published procedure for purification





Gel using the new Galli Process contained in this application




1. Molecular Weight Marker
2. Prior Process Carson (nonpublished) Batch 2000C9001 Reference Reduced (7.5  $\mu\text{g}$ )
3. Same Batch 2000C9001 Reference Reduced (5.0  $\mu\text{g}$ )
4. Galli Process Enzyme Batch P10006 (5.0  $\mu\text{g}$ )

**FIGURE 2**

**FIGURE 3A IDURONIDASE PRODUCTION USING THE GALLI PROCESS****Iduronidase Enzyme Activity During Production****FIGURE 3B. IDURONIDASE PRODUCTION USING BUTYRATE INDUCTION**





**FIGURE 4**

# Urinary GAG Excretion During Enzyme Therapy




FIGURE 5




FIGURE 6

# Shoulder flexion to 104 weeks in four"patients with most restriction




FIGURE 7

# Sleep Apnea Improves





FIGURE 8

# Apneas + Hypopneas During Sleep Pre and Post Treatment



JOM001 AHC002 RCD003 SSH004 SWD005 GMD006 JAN007 N-M008 CEL009 BBG010

FIGURE 9

# Pulmonary Function Tests in GMD006




FIGURE 10



# Increased Height Growth Velocity





FIGURE 11



**FIGURE 12.****COMPARISON OF HOST PROTEIN CONTAMINATION BETWEEN A PRIOR AND THE NEW GALLI PROCESS****Chinese Hamster Ovary Host Protein Contamination by ELISA Assay**

<b>SOURCE AND BATCH NUMBER</b>	<b>CHOP PROTEIN CONTAMINATION (microgram per milligram)</b>	<b>PERCENT CHOP CONTAMINATION</b>	<b>PURITY OF THE ENZYME FROM CHOP</b>
Prior Process (Carson/REI)			
C9002	14	1.4%	98.6%
C9003	24	2.4%	97.6%
C9004	16	1.6%	98.4%
New Process (Galli)			
P1003	<1.3	<0.13%	>99.9%
P1006	1.2	0.12%	99.9%
P1007	<0.6	<0.06%	>99.9%
P1008	<0.67	<0.067%	>99.9%

**FIGURE 12**

**Comparison of Galli and Carson Material**

- 1 Marker
- 2 Galli Referenced-0201
- 3 Carson C9002

5ug/lane

**FIGURE 13**

## SEQUENCE LISTING

<110> BIOMARIN PHARMACEUTICAL, INC.

<120> METHODS FOR TREATING DISEASES CAUSED BY  
DEFICIENCIES OF RECOMBINANT ALPHA-L-IDURONIDASE

<130> 008000051PC01

<140> TO BE ASSIGNED

<141> 2001-11-09

<150> 09/439,923

<151> 2000-11-09

<150> 09/439,923

<151> 1999-11-12

<160> 2

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 6200

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1558) ... (3510)

<400> 1

acggatcgg	gagatctccc	gatcccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
cgcatagtt	aagccagtat	ctgctcccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
jagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
tagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
attattgac	tagttattaa	tagtaatcaa	ttacgggggc	attagttcat	agcccatata	300
ggagtcccg	cgttacataa	cttacggtaa	atggcccggc	tggetgaccg	cccaacgacc	360
cgcccaatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
tgacgtca	atgggtggac	tatttacggt	aaactgcccc	cttggcagta	catcaagtgt	480
catatgcc	aagtaagccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
gcccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
gctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
tcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatgggcg	780
aggcgtgt	acggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
gcttaact	ggcttatcga	aattaatacg	actcactata	gggagaccca	agcttcgcag	900
ttcctgcg	gctgctacag	tgtgtccagc	gtcctgectg	gctgtgctga	gcgctggaac	960
tggcgcac	cattcaagtg	cacagttacc	catcctgagt	ctggcacctt	aactggcaca	1020
tgccaaag	tcacaggtga	gctcagatgc	ataccaggac	attgtatgac	gttccctgct	1080
catgcctg	ctttcttcct	ataatacaga	tgtccaacta	actgctcatg	tccttatatc	1140
agaggga	attggagcta	tctgaggac	tgccagaag	ggaaggcgag	aggggtcttg	1200
ctccttgt	ctgagccata	actcttcttt	ctaccttcca	gtgaacacct	tcccaccca	1260
tccacctg	ctaccgccgc	cgtcggagga	gctggccctg	aatgagctct	tgtccctgac	1320
gcctgggtg	cgagctttca	accctaaga	agtgtgggtg	cgatggctgc	atggaaatga	1380

ggagctgtcc ccagaaagct acctagtgtt tgagccccta aaggagccag gcgagggagc 1440  
 caccacctac ctggtgacaa gcgtgttgcg tgtatcagct gaaagcttga tatcgaattc 1500  
 cggaggcgga accggcagtg cagcccgaag ccccgagtc cccgagcacg cgtggcc atg 1560  
 Met  
 1

cgt ccc ctg cgc ccc cgc gcc gcg ctg ctg gcg ctc ctg gcc tcg ctc 1608  
 Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu Ala Ser Leu  
 5 10 15

ctg gcc gcg ccc ccg gtg gcc ccg gcc gag gcc ccg cac ctg gtg cat 1656  
 Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val His  
 20 25 30

gtg gac gcg gcc cgc gcg ctg tgg ccc ctg cgg cgc ttc tgg agg agc 1704  
 Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg Ser  
 35 40 45

aca ggc ttc tgc ccc ccg ctg cca cac agc cag gct gac cag tac gtg 1752  
 Thr Gly Phe Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr Val  
 50 55 60 65

ctc agc tgg gac cag cag ctc aac ctc gcc tat gtg ggc gcc gtc cct 1800  
 Leu Ser Trp Asp Gln Gln Leu Asn Leu Ala Tyr Val Gly Ala Val Pro  
 70 75 80

cac cgc ggc atc aag cag gtc cgg acc cac tgg ctg ctg gag ctt gtc 1848  
 His Arg Gly Ile Lys Gln Val Arg Thr His Trp Leu Leu Glu Leu Val  
 85 90 95

acc acc agg ggg tcc act gga cgg gcc ctg agc tac aac ttc acc cac 1896  
 Thr Thr Arg Gly Ser Thr Gly Arg Gly Leu Ser Tyr Asn Phe Thr His  
 100 105 110

ctg gac ggg tac ctg gac ctt ctc agg gag aac cag ctc ggg ttt gag 1944  
 Leu Asp Gly Tyr Leu Asp Leu Leu Arg Glu Asn Gln Leu Gly Phe Glu  
 115 120 125

ctg atg ggc agc gcc tcg gcc cac ttc act gac ttt gag gac aag cag 1992  
 Leu Met Gly Ser Ala Ser Gly His Phe Thr Asp Phe Glu Asp Lys Gln  
 130 135 140 145

cag gtg ttt gag tgg aag gac ttg gtc tcc agc ctg gcc agg aga tac 2040  
 Gln Val Phe Glu Trp Lys Asp Leu Val Ser Ser Leu Ala Arg Arg Tyr  
 150 155 160

atc ggt agg tac gga ctg gcg cat gtt tcc aag tgg aac ttc gag acg 2088  
 Ile Gly Arg Tyr Gly Leu Ala His Val Ser Lys Trp Asn Phe Glu Thr  
 165 170 175

tgg aat gag cca gac cac cac gac ttt gac aac gtc tcc atg acc atg 2136  
 Trp Asn Glu Pro Asp His His Asp Phe Asp Asn Val Ser Met Thr Met  
 180 185 190

caa ggc ttc ctg aac tac tac gat gcc tgc tcg gag ggt ctg cgc gcc 2184  
 Gln Gly Phe Leu Asn Tyr Tyr Asp Ala Cys Ser Glu Gly Leu Arg Ala  
 195 200 205

gcc agc ccc gcc ctg cgg ctg gga ggc ccc ggc gac tcc ttc cac acc	2232
Ala Ser Pro Ala Leu Arg Leu Gly Gly Pro Gly Asp Ser Phe His Thr	
210 215 220 225	
cca ccg cga tcc ccg ctg agc tgg ggc ctc ctg cgc cac tgc cac gac	2280
Pro Pro Arg Ser Pro Leu Ser Trp Gly Leu Leu Arg His Cys His Asp	
230 235 240	
ggc acc aac ttc ttc act ggg gag gcg ggc gtg cgg ctg gac tac atc	2328
Gly Thr Asn Phe Phe Thr Gly Glu Ala Gly Val Arg Leu Asp Tyr Ile	
245 250 255	
tcc ctc cac agg aag ggt gcg cgc agc tcc atc tcc atc ctg gag cag	2376
Ser Leu His Arg Lys Gly Ala Arg Ser Ser Ile Ser Ile Leu Glu Gln	
260 265 270	
gag aag gtc gtc gcg cag cag atc cgg cag ctc ttc ccc aag ttc gcg	2424
Glu Lys Val Val Ala Gln Gln Ile Arg Gln Leu Phe Pro Lys Phe Ala	
275 280 285	
gac acc ccc att tac aac gac gag gcg gac ccg ctg gtg ggc tgg tcc	2472
Asp Thr Pro Ile Tyr Asn Asp Glu Ala Asp Pro Leu Val Gly Trp Ser	
290 295 300 305	
ctg cca cag ccg tgg agg gcg gac gtg acc tac gcg gcc atg gtg gtg	2520
Leu Pro Gln Pro Trp Arg Ala Asp Val Thr Tyr Ala Ala Met Val Val	
310 315 320	
aag gtc atc gcg cag cat cag aac ctg cta ctg gcc aac acc acc tcc	2568
Lys Val Ile Ala Gln His Gln Asn Leu Leu Leu Ala Asn Thr Thr Ser	
325 330 335	
gcc ttc ccc tac gcg ctc ctg agc aac gac aat gcc ttc ctg agc tac	2616
Ala Phe Pro Tyr Ala Leu Leu Ser Asn Asp Asn Ala Phe Leu Ser Tyr	
340 345 350	
cac ccg cac ccc ttc gcg cag cgc acg ctc acc gcg cgc ttc cag gtc	2664
His Pro His Pro Phe Ala Gln Arg Thr Leu Thr Ala Arg Phe Gln Val	
355 360 365	
aac aac acc cgc ccg ccg cac gtg cag ctg ttg cgc aag ccg gtg ctc	2712
Asn Asn Thr Arg Pro Pro His Val Gln Leu Leu Arg Lys Pro Val Leu	
370 375 380 385	
acg gcc atg ggg ctg ctg gcg ctg ctg gat gag gag cag ctc tgg gcc	2760
Thr Ala Met Gly Leu Leu Ala Leu Leu Asp Glu Glu Gln Leu Trp Ala	
390 395 400	
gaa gtg tcg cag gcc ggg acc gtc ctg gac agc aac cac acg gtg ggc	2808
Glu Val Ser Gln Ala Gly Thr Val Leu Asp Ser Asn His Thr Val Gly	
405 410 415	
gtc ctg gcc agc gcc cac cgc ccc cag ggc ccg gcc gac gcc tgg cgc	2856
Val Leu Ala Ser Ala His Arg Pro Gln Gly Pro Ala Asp Ala Trp Arg	
420 425 430	

gcc gcg gtg ctg atc tac gcg agc gac gac acc cgc gcc cac ccc aac	2904
Ala Ala Val Leu Ile Tyr Ala Ser Asp Asp Thr Arg Ala His Pro Asn	
435 440 445	
cgc agc gtc gcg gtg acc ctg cgg ctg cgc ggg gtg ccc ccc ggc ccg	2952
Arg Ser Val Ala Val Thr Leu Arg Leu Arg Gly Val Pro Pro Gly Pro	
450 455 460 465	
ggc ctg gtc tac gtc acg cgc tac ctg gac aac ggg ctc tgc agc ccc	3000
Gly Leu Val Tyr Val Thr Arg Tyr Leu Asp Asn Gly Leu Cys Ser Pro	
470 475 480	
gac ggc gag tgg cgg cgc ctg ggc cgg ccc gtc ttc ccc acg gca gag	3048
Asp Gly Glu Trp Arg Arg Leu Gly Arg Pro Val Phe Pro Thr Ala Glu	
485 490 495	
cag ttc cgg cgc tag cgc gcg gct gag gac ccg gtg gcc gcg gcg ccc	3096
Gln Phe Arg Arg * Arg Ala Ala Glu Asp Pro Val Ala Ala Ala Pro	
500 505 510	
cgc ccc tta ccc gcc ggc ggc cgc ctg agg ctg cgc ccc gcg ctg cgg	3144
Arg Pro Leu Pro Ala Gly Gly Arg Leu Arg Leu Arg Pro Ala Leu Arg	
515 520 525	
ctg ccg tcg ctt ttg ctg gtg cac gtg tgt gcg cgc ccc gag aag ccg	3192
Leu Pro Ser Leu Leu Leu Val His Val Cys Ala Arg Pro Glu Lys Pro	
530 535 540	
ccc ggg cag gtc acg cgg ctc cgc gcc ctg ccc ctg acc caa ggg cag	3240
Pro Gly Gln Val Thr Arg Leu Arg Ala Leu Pro Leu Thr Gln Gly Gln	
545 550 555 560	
ctg gtt ctg gtc tgg tcg gat gaa cac gtg ggc tcc aag tgc ctg tgg	3288
Leu Val Leu Val Trp Ser Asp Glu His Val Gly Ser Lys Cys Leu Trp	
565 570 575	
aca tac gag atc cag ttc tct cag gac ggt aag gcg tac acc ccg gtc	3336
Thr Tyr Glu Ile Gln Phe Ser Gln Asp Gly Lys Ala Tyr Thr Pro Val	
580 585 590	
agc agg aag cca tcg acc ttc aac ctc ttt gtg ttc agc cca gac aca	3384
Ser Arg Lys Pro Ser Thr Phe Asn Leu Phe Val Phe Ser Pro Asp Thr	
595 600 605	
ggg gct gtc tct ggc tcc tac cga gtt cga gcc ctg gac tac tgg gcc	3432
Gly Ala Val Ser Gly Ser Tyr Arg Val Arg Ala Leu Asp Tyr Trp Ala	
610 615 620	
cga cca ggc ccc ttc tcg gac cct gtg ccg tac ctg gag gtc cct gtg	3480
Arg Pro Gly Pro Phe Ser Asp Pro Val Pro Tyr Leu Glu Val Pro Val	
625 630 635 640	
cca aga ggg ccc cca tcc ccg ggc aat cca tgagcctgtg ctgagcccca	3530
Pro Arg Gly Pro Ser Pro Gly Asn Pro	
645 650	
gtgggttgca cctccaccgg cagtcagcga gctggggctg cactgtgccc atgctgccct	3590

```

cccatcacc cctttgcaat atatttttat attttaaaaa aaaaaaaaaa aaaaaaaaaa 3650
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aattcctgca 3710
gcccggggga tccactagtt ctagagggcc cgtttaaaacc cgctgatcag cctcgactgt 3770
gccttctagt tgccagccat ctggtgtttg cccctccccg gtgccttctt tgaccttgga 3830
aggtgccact cccactgtcc ttctctaata aaatgaggaa attgcatcgc attgtctgag 3890
taggtgtcat tctattctgg ggggtggggg ggggcaggac agcaaggggg aggattggga 3950
agacaatagc aggcattgtg aggaaagggt gggctctatg gcttctgagg cggaaaagac 4010
cagctggggc tcgagagctt ggcgtaata tggctatagc tgtttctgt gtgaaattgt 4070
tatccgctca caattccaca caacatacga gccggaagca taaagtgtaa agcctggggg 4130
gcctaattgag tgagctaaact cacattaatt gcgttgccgt cactgcccgc tttccagtcg 4190
ggaaacctgt cgtgccagct gcattaatga atcgcccaac gcgcggggag aggcggtttg 4250
cgtattgggc gctcttccgc ttctctgcct actgactcgc tgcgctcggg cgttcggctg 4310
cggcgagcgg tatcagctca ctcaaaggcg gtaatacggg tatccacaga atcaggggat 4370
aacgcaggaa agaacaatgt agcaaaaggc cagcaaaagg ccaggaaaccg taaaaaggcc 4430
gcgttgctgg cgtttttcca taggtctcgc cccctgacg agcatcacia aaatcgacgc 4490
tcaagtcaga ggtggcgaaa cccgacagga ctataagat accaggcgtt tccccctgga 4550
agctccctcg tgcgctctcc tgttccgacc ctgcccgtta ccggatacct gtccgccttt 4610
ctcccttcgg gaagcgtggc gctttctcaa tgctcacgt gtaggatatc cagttcgggtg 4670
taggtcggtc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc 4730
gccttatccg gtaactatcg tcttgagtc aaccgggtaa gacacgactt atcgccactg 4790
gcagcagcca ctggtaacag gattagcaga cgcagggtatg taggcggtgc tacagagttc 4850
ttgaagtgtt ggcctaacta cggctacact agaaggacag tatttggtat ctgcgctctg 4910
ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa acaaaccacc 4970
gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct 5030
caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaaacga aaactcacgt 5090
taagggattt tggctatgag attatcaaaa aggatcttca cctagatcct tttaaattaa 5150
aaatgaagtt ttaaatcaat ctaaaagtata tatgagtaaa cttggtctga cagttacca 5210
tgcttaatac ctgaggcacc tatctcagcg atctgtctat ttcggttcac catagttgcc 5270
tgactccccg tctgttagat aactacgata cgggaggggt taccatctgg cccagtgct 5330
gcaatgatac cgcgagacc acgctcaccg gctccagatt tatcagcaat aaaccagcca 5390
gccggaaggg ccgagcgcag aagtggctct gcaactttat ccgcctccat ccagtcatt 5450
aattgttgcc gggagctag agtaagtagt tcgccagtta atagtttgcg caacgttgtt 5510
gccattgcta caggcatcgt ggtgtcacgc tctcggttg gtatggcttc attcagctcc 5570
ggttcccaac gatcaaggcg agttacatga tccccatgt tgtgcaaaaa agcgggttagc 5630
tccttcggtc tcccgatcgt tgtcagaagt aagttggcg cagtggtatc actcatggtt 5690
atggcagcac tgcataatto tcttactgtc atgccatccg taagatgctt ttctgtgact 5750
ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc 5810
ccggcgctcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt gctcatcatt 5870
ggaaaacggt cttcggggcg aaaactctca aggatcttac cgctgttgag atccagttcg 5930
atgtaaccca ctctgtcacc caactgatct tcagcatctt ttactttcac cagcgtttct 5990
gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc gacacgaaa 6050
tggtgaatac tcatactctt cctttttcaa tattattgaa gcatttatca gggttattgt 6110
ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc 6170
acatttcccc gaaaagtgcc acctgacgtc 6200

```

&lt;210&gt; 2

&lt;211&gt; 650

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Arg Pro Leu Arg Pro Arg Ala Ala Leu Leu Ala Leu Leu Ala Ser
 1             5             10            15
Leu Leu Ala Ala Pro Pro Val Ala Pro Ala Glu Ala Pro His Leu Val
      20            25            30
His Val Asp Ala Ala Arg Ala Leu Trp Pro Leu Arg Arg Phe Trp Arg
      35            40            45

```

Ser Thr Gly Phe Cys Pro Pro Leu Pro His Ser Gln Ala Asp Gln Tyr  
 50 55 60  
 Val Leu Ser Trp Asp Gln Gln Leu Asn Leu Ala Tyr Val Gly Ala Val  
 65 70 75 80  
 Pro His Arg Gly Ile Lys Gln Val Arg Thr His Trp Leu Leu Glu Leu  
 85 90 95  
 Val Thr Thr Arg Gly Ser Thr Gly Arg Gly Leu Ser Tyr Asn Phe Thr  
 100 105 110  
 His Leu Asp Gly Tyr Leu Asp Leu Leu Arg Glu Asn Gln Leu Gly Phe  
 115 120 125  
 Glu Leu Met Gly Ser Ala Ser Gly His Phe Thr Asp Phe Glu Asp Lys  
 130 135 140  
 Gln Gln Val Phe Glu Trp Lys Asp Leu Val Ser Ser Leu Ala Arg Arg  
 145 150 155 160  
 Tyr Ile Gly Arg Tyr Gly Leu Ala His Val Ser Lys Trp Asn Phe Glu  
 165 170 175  
 Thr Trp Asn Glu Pro Asp His His Asp Phe Asp Asn Val Ser Met Thr  
 180 185 190  
 Met Gln Gly Phe Leu Asn Tyr Tyr Asp Ala Cys Ser Glu Gly Leu Arg  
 195 200 205  
 Ala Ala Ser Pro Ala Leu Arg Leu Gly Gly Pro Gly Asp Ser Phe His  
 210 215 220  
 Thr Pro Pro Arg Ser Pro Leu Ser Trp Gly Leu Leu Arg His Cys His  
 225 230 235 240  
 Asp Gly Thr Asn Phe Phe Thr Gly Glu Ala Gly Val Arg Leu Asp Tyr  
 245 250 255  
 Ile Ser Leu His Arg Lys Gly Ala Arg Ser Ser Ile Ser Ile Leu Glu  
 260 265 270  
 Gln Glu Lys Val Val Ala Gln Gln Ile Arg Gln Leu Phe Pro Lys Phe  
 275 280 285  
 Ala Asp Thr Pro Ile Tyr Asn Asp Glu Ala Asp Pro Leu Val Gly Trp  
 290 295 300  
 Ser Leu Pro Gln Pro Trp Arg Ala Asp Val Thr Tyr Ala Ala Met Val  
 305 310 315 320  
 Val Lys Val Ile Ala Gln His Gln Asn Leu Leu Leu Ala Asn Thr Thr  
 325 330 335  
 Ser Ala Phe Pro Tyr Ala Leu Leu Ser Asn Asp Asn Ala Phe Leu Ser  
 340 345 350  
 Tyr His Pro His Pro Phe Ala Gln Arg Thr Leu Thr Ala Arg Phe Gln  
 355 360 365  
 Val Asn Asn Thr Arg Pro Pro His Val Gln Leu Leu Arg Lys Pro Val  
 370 375 380  
 Leu Thr Ala Met Gly Leu Leu Ala Leu Leu Asp Glu Glu Gln Leu Trp  
 385 390 395 400  
 Ala Glu Val Ser Gln Ala Gly Thr Val Leu Asp Ser Asn His Thr Val  
 405 410 415  
 Gly Val Leu Ala Ser Ala His Arg Pro Gln Gly Pro Ala Asp Ala Trp  
 420 425 430  
 Arg Ala Ala Val Leu Ile Tyr Ala Ser Asp Asp Thr Arg Ala His Pro  
 435 440 445  
 Asn Arg Ser Val Ala Val Thr Leu Arg Leu Arg Gly Val Pro Pro Gly  
 450 455 460  
 Pro Gly Leu Val Tyr Val Thr Arg Tyr Leu Asp Asn Gly Leu Cys Ser  
 465 470 475 480  
 Pro Asp Gly Glu Trp Arg Arg Leu Gly Arg Pro Val Phe Pro Thr Ala  
 485 490 495  
 Glu Gln Phe Arg Arg Arg Ala Ala Glu Asp Pro Val Ala Ala Ala Pro



Arg	Pro	Leu	Pro	Ala	Gly	Gly	Arg	Leu	Arg	Leu	Arg	Pro	Ala	Leu	Arg
		515					520					525			
Leu	Pro	Ser	Leu	Leu	Leu	Val	His	Val	Cys	Ala	Arg	Pro	Glu	Lys	Pro
		530				535						540			
Pro	Gly	Gln	Val	Thr	Arg	Leu	Arg	Ala	Leu	Pro	Leu	Thr	Gln	Gly	Gln
545					550					555					560
Leu	Val	Leu	Val	Trp	Ser	Asp	Glu	His	Val	Gly	Ser	Lys	Cys	Leu	Trp
				565					570						575
Thr	Tyr	Glu	Ile	Gln	Phe	Ser	Gln	Asp	Gly	Lys	Ala	Tyr	Thr	Pro	Val
			580					585					590		
Ser	Arg	Lys	Pro	Ser	Thr	Phe	Asn	Leu	Phe	Val	Phe	Ser	Pro	Asp	Thr
		595					600					605			
Gly	Ala	Val	Ser	Gly	Ser	Tyr	Arg	Val	Arg	Ala	Leu	Asp	Tyr	Trp	Ala
		610				615					620				
Arg	Pro	Gly	Pro	Phe	Ser	Asp	Pro	Val	Pro	Tyr	Leu	Glu	Val	Pro	Val
625					630					635					640
Pro	Arg	Gly	Pro	Pro	Ser	Pro	Gly	Asn	Pro						
				645				650							

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number  
**WO 02/038171 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/47**,  
A61P 43/00 // C12N 9/24, 15/56

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number: PCT/US01/47835

(22) International Filing Date:  
9 November 2001 (09.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/711,205 9 November 2000 (09.11.2000) US

(71) Applicant (for all designated States except US):  
**BIOMARIN PHARMACEUTICAL, INC.** [US/US];  
371 Bel Marin Keys Boulevard, Suite 210, Novato, CA  
94949 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KAKKIS, Emil, D.**  
[US/US]; 2512 Laguna Vista Drive, Novato, CA 94949  
(US).

(74) Agent: **HALLUIN, Albert, P.**; Howrey Simon Arnold &  
White, LLP, 301 Ravenswood Avenue, Menlo Park, CA  
94025 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GI, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB,  
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,  
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,  
ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,  
SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),  
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for the following desig-  
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,  
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,  
YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ,  
SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,  
SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG)

**Published:**

— with international search report

(88) Date of publication of the international search report:  
24 April 2003

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF  $\alpha$ -L-IDURONIDASE

(57) Abstract: The present invention provides a formulation comprising a pharmaceutical composition comprising a human re-  
combinant  $\alpha$ -L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a  
pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including  
 $\alpha$ -L-iduronidase deficiency and mucopolysaccharidosis I (MPS I) by administering said formulation.

WO 02/038171 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/47835

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/47 A61P43/00 //C12N9/24,C12N15/56

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>"BioMarin and Genzyme Report Positive One Year Summary Data For MPS-1 Patients"</p> <p>GENZYME GENERAL WEB SITE: WWW.GENZYME.COM, 'Online! 14 September 1999 (1999-09-14), XP002209337</p> <p>Retrieved from the Internet:</p> <p>&lt;URL:http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&amp;STORY=/www/story/09-14-1999/0001020970&gt; 'retrieved on 2002-08-08! the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	14-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

16 August 2002

Date of mailing of the international search report

06/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Lechner, O

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/47835

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 99 58691 A (HARBOR UCLA) 18 November 1999 (1999-11-18) abstract claims 1-41 page 3 -page 5 page 17, paragraphs 2,3 page 20, paragraphs 4-6 page 16, line 3-8 -----	1,2,4, 14-28 1-28
X	KAKKIS E D ET AL: "LONG-TERM AND HIGH-DOSE TRIALS OF ENZYME REPLACEMENT THERAPY IN THE CANINE MODEL OF MUCOPOLYSACCHARIDOSIS I" BIOCHEMICAL AND MOLECULAR MEDICINE, ORLANDO, FL, US, vol. 58, no. 2, August 1996 (1996-08), pages 156-167, XP000862844 ISSN: 1077-3150 -----	1,2,4, 14-28
Y	the whole document -----	1-28
Y	EP 1 029 548 A (ASAHI CHEMICAL IND) 23 August 2000 (2000-08-23) abstract examples 1-92 tables 1-12 -----	1-13

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/47835

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 14-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 14-17 and 21-28 (only partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 14-17 and 21-28 (only partially)

Present claims 14-17 and 21-28 relate to an extremely large number of possible diseases/pathologic conditions defined by the pathobiochemical mechanism causing the diseases/pathologic condition, i.e. diseases caused all or in part by a deficiency in alpha-L-iduronidase, patient(s) demonstrating 1% or less of a normal alpha-L-iduronidase activity, normal complement mediation clinical allergic reactions. In fact, the claims contain so many options that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely mucopolysaccharidosis (MPS), MPS I, Hurler's disease, Scheie syndrome and Hurler-Scheie syndrome.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No

PCT/US 01/47835

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9958691	A	18-11-1999	AU 4072499 A	29-11-1999
			BR 9910323 A	30-01-2001
			CA 2328518 A1	18-11-1999
			CN 1300323 T	20-06-2001
			EP 1078075 A2	28-02-2001
			JP 2002514429 T	21-05-2002
			WO 9958691 A2	18-11-1999
EP 1029548	A	23-08-2000	AU 729876 B2	15-02-2001
			AU 9460398 A	03-05-1999
			CA 2306206 A1	22-04-1999
			EP 1029548 A1	23-08-2000
			CN 1275916 T	06-12-2000
			WO 9918994 A1	22-04-1999